{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "c:\\Users\\kthk1\\Documents\\NUS\\AI_Singapore\\Nvidia\\Nvidia-RAG\\venv\\Lib\\site-packages\\tqdm\\auto.py:21: TqdmWarning: IProgress not found. Please update jupyter and ipywidgets. See https://ipywidgets.readthedocs.io/en/stable/user_install.html\n",
      "  from .autonotebook import tqdm as notebook_tqdm\n"
     ]
    }
   ],
   "source": [
    "from dotenv import load_dotenv\n",
    "import os\n",
    "\n",
    "from llama_index.llms.azure_openai import AzureOpenAI\n",
    "from llama_index.embeddings.azure_openai import AzureOpenAIEmbedding\n",
    "from llama_index.core.node_parser import SemanticSplitterNodeParser, SentenceSplitter\n",
    "from llama_index.core import VectorStoreIndex, SimpleDirectoryReader, StorageContext, Document\n",
    "from llama_index.vector_stores.milvus import MilvusVectorStore\n",
    "\n",
    "from llama_index.embeddings.nvidia import NVIDIAEmbedding\n",
    "from llama_index.llms.nvidia import NVIDIA\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[0.003818511962890625, 0.0019378662109375, -0.00588226318359375, -0.007709503173828125, 0.022247314453125, 0.00989532470703125, -0.01678466796875, -0.035247802734375, 0.0207061767578125, 0.0235748291015625, 0.004669189453125, -0.006534576416015625, -0.020599365234375, 0.04034423828125, -0.0152740478515625, 0.0245361328125, -0.0262603759765625, 0.01873779296875, -0.00909423828125, -0.01462554931640625, 0.00749969482421875, 0.0082550048828125, -0.0211029052734375, -0.0029926300048828125, -0.00937652587890625, 0.004192352294921875, 0.0208587646484375, -0.004535675048828125, 0.0182342529296875, 0.0124053955078125, -0.01061248779296875, -0.0121917724609375, -0.015869140625, 0.00823211669921875, -0.027313232421875, 0.007259368896484375, 0.006702423095703125, -0.007572174072265625, 0.008544921875, -0.0194854736328125, -0.01593017578125, -0.0202484130859375, 0.00884246826171875, -0.01131439208984375, -0.0204925537109375, -0.0248870849609375, 0.016754150390625, -0.00563812255859375, 0.00304412841796875, -0.01556396484375, 0.033416748046875, 0.0106353759765625, 0.005023956298828125, 0.035919189453125, 0.00011974573135375977, 0.003330230712890625, 0.009796142578125, -0.017364501953125, -0.01132965087890625, 0.0248870849609375, -0.008209228515625, -0.0166473388671875, 0.00508880615234375, -0.0280303955078125, -0.00312042236328125, -0.002490997314453125, 0.0018529891967773438, 0.00479888916015625, 0.01175689697265625, 0.01593017578125, -0.00722503662109375, -0.0024394989013671875, 0.028472900390625, 0.01464080810546875, -0.01120758056640625, 0.0194549560546875, 0.0022735595703125, -0.00775146484375, -0.01172637939453125, -0.0147705078125, 0.0095672607421875, -0.007965087890625, 0.022674560546875, -0.0172119140625, 0.006252288818359375, 0.03863525390625, -0.0208282470703125, 0.002948760986328125, 0.005321502685546875, -0.0205230712890625, 0.004058837890625, 0.0306549072265625, -0.00439453125, -0.0308837890625, -0.0094757080078125, 0.01001739501953125, -0.0011730194091796875, -0.004924774169921875, 0.0170135498046875, -0.00864410400390625, 0.01800537109375, -0.00342559814453125, 0.0245361328125, -0.007904052734375, -0.01224517822265625, -0.028656005859375, 0.006092071533203125, 0.013885498046875, -0.0145721435546875, 0.01111602783203125, 0.0042877197265625, -0.007663726806640625, 0.004283905029296875, 0.00550079345703125, -0.00832366943359375, 0.01325225830078125, 0.0089569091796875, 0.00489044189453125, 0.0031414031982421875, 0.00335693359375, 0.00933074951171875, -0.00032830238342285156, 0.0025081634521484375, 0.01953125, 0.003963470458984375, 0.002410888671875, -0.01441192626953125, -0.0108489990234375, 0.006809234619140625, 0.0020503997802734375, 0.00536346435546875, 0.0292816162109375, 0.017120361328125, -0.0253753662109375, -0.004161834716796875, -0.005199432373046875, -0.0106658935546875, -0.003971099853515625, -0.028900146484375, -0.0210418701171875, -0.019927978515625, -0.018829345703125, -0.005008697509765625, -0.0110931396484375, 0.0032520294189453125, -0.0009851455688476562, -0.0064697265625, 0.00782012939453125, 0.017425537109375, 0.0110321044921875, 0.01090240478515625, -0.01288604736328125, 0.00075531005859375, -0.008087158203125, 0.01306915283203125, -0.023681640625, 0.003566741943359375, 0.0099639892578125, -0.00984954833984375, -0.0109710693359375, 0.0004968643188476562, 0.014892578125, -0.01088714599609375, -0.016204833984375, -0.0210723876953125, 0.0097808837890625, 0.002971649169921875, 0.0018377304077148438, 0.0007891654968261719, -0.00954437255859375, -0.0207672119140625, -0.002178192138671875, 0.0020503997802734375, 0.01088714599609375, -0.000682830810546875, 0.00604248046875, 0.0198822021484375, 0.01132965087890625, -0.00893402099609375, -0.0179443359375, 0.0164031982421875, 0.005268096923828125, 0.01537322998046875, 0.00441741943359375, -0.005146026611328125, 0.0006413459777832031, -0.0087127685546875, 0.0104217529296875, -0.01305389404296875, 0.00472259521484375, 0.0152740478515625, 0.007373809814453125, -0.0026950836181640625, -0.01629638671875, 0.00756072998046875, 0.0153045654296875, -0.0016050338745117188, 0.00775146484375, 0.003734588623046875, 0.0007867813110351562, 0.00965118408203125, 0.026763916015625, 0.0330810546875, -0.00351715087890625, 0.04132080078125, 0.0151214599609375, 0.030792236328125, 0.00885009765625, 0.005069732666015625, -0.0063018798828125, 0.0222625732421875, -0.007289886474609375, -0.02093505859375, 0.01322174072265625, -0.0085296630859375, 0.01317596435546875, 0.003692626953125, 0.0011796951293945312, -0.02020263671875, -0.0124664306640625, 0.022796630859375, 0.0078582763671875, -0.0202178955078125, -0.005878448486328125, 0.007709503173828125, -0.0217742919921875, 0.0217132568359375, 0.017791748046875, 0.0033893585205078125, -0.005725860595703125, -0.00934600830078125, -0.01041412353515625, 0.0041961669921875, 0.021209716796875, 0.01092529296875, 0.0158843994140625, -0.007518768310546875, -0.0095977783203125, 0.006343841552734375, -0.0204010009765625, -0.006412506103515625, 0.0216064453125, -0.0097503662109375, 0.00829315185546875, 0.01290130615234375, 0.0308837890625, 0.00658416748046875, 0.003940582275390625, -0.0099334716796875, 0.00909423828125, -0.00014126300811767578, -0.0103302001953125, 0.007099151611328125, 0.010498046875, -0.0038604736328125, -0.00392913818359375, -0.025970458984375, -0.00691986083984375, 0.01160430908203125, 0.00347137451171875, -0.020477294921875, 0.017669677734375, -0.0015926361083984375, -0.01800537109375, -0.00547027587890625, -0.003955841064453125, -0.0159912109375, 0.014404296875, 0.00972747802734375, -0.043121337890625, 0.0027008056640625, 0.005359649658203125, -0.020538330078125, -0.0014247894287109375, -0.0013475418090820312, -0.0073394775390625, -0.0008702278137207031, -0.0088043212890625, 0.0009646415710449219, 0.01336669921875, 0.005031585693359375, -0.0110931396484375, -0.0008416175842285156, -0.01329803466796875, -0.0030612945556640625, 0.01250457763671875, -0.0112762451171875, -0.01409149169921875, -0.0169525146484375, -0.01129150390625, -0.003849029541015625, 0.0201873779296875, -0.08135986328125, -0.0268096923828125, -0.0088653564453125, -0.030670166015625, -0.023651123046875, 0.0172119140625, 0.011749267578125, -0.01123809814453125, 0.013702392578125, 0.0161590576171875, 0.003917694091796875, 0.00841522216796875, -0.0022430419921875, -0.01451873779296875, -0.0057373046875, -0.003932952880859375, -0.0011320114135742188, 0.0031719207763671875, 0.01085662841796875, 0.01221466064453125, 0.025299072265625, 0.0190277099609375, 0.0133819580078125, -0.0115966796875, 0.025177001953125, 0.002223968505859375, 0.01282501220703125, 0.007160186767578125, 0.004302978515625, -0.026397705078125, 0.0112762451171875, 0.01265716552734375, -0.0318603515625, -0.021728515625, 0.01209259033203125, 0.005428314208984375, -0.00473785400390625, -0.0280303955078125, -0.00778961181640625, -0.005275726318359375, -0.029327392578125, -0.01003265380859375, 0.0010623931884765625, -0.0158233642578125, 0.0151824951171875, 0.00146484375, 0.029693603515625, -0.00226593017578125, 0.0117645263671875, -0.007465362548828125, 0.0114288330078125, 0.01873779296875, 0.0016469955444335938, -0.0005574226379394531, -0.0203094482421875, -0.00710296630859375, 0.0151824951171875, 0.002162933349609375, 0.0106353759765625, -0.01262664794921875, -0.0015125274658203125, 0.0111541748046875, 0.0012598037719726562, -0.01543426513671875, 0.037872314453125, 0.022674560546875, -0.0125885009765625, -0.0110321044921875, 0.019439697265625, -0.005001068115234375, 0.01198577880859375, 0.008392333984375, 0.0033512115478515625, -0.00030612945556640625, 0.0185394287109375, 0.019378662109375, 0.01432037353515625, -0.008697509765625, -0.01116943359375, -0.003566741943359375, -0.0108642578125, 0.0010738372802734375, 0.0038318634033203125, -0.0052337646484375, 0.007175445556640625, -0.00041031837463378906, 0.01214599609375, 0.013946533203125, 0.00577545166015625, 0.002574920654296875, 0.0082550048828125, -0.002162933349609375, -0.01055145263671875, 0.01538848876953125, -0.00020384788513183594, -0.00659942626953125, -0.0035190582275390625, -0.00640106201171875, 0.00844573974609375, 0.00921630859375, -0.0086669921875, 0.0088348388671875, -0.00048089027404785156, -0.004207611083984375, -0.005580902099609375, 0.0095672607421875, 0.0208740234375, -0.0009646415710449219, 0.0029888153076171875, -0.00400543212890625, 0.0036220550537109375, 0.012176513671875, -0.0089874267578125, -0.00030922889709472656, 0.019012451171875, -0.00437164306640625, 0.0003287792205810547, 0.015777587890625, -0.0377197265625, -0.01117706298828125, 0.0092010498046875, 0.0267791748046875, 0.01244354248046875, 0.0026092529296875, -0.003665924072265625, -0.005222320556640625, -0.010162353515625, -0.0033416748046875, 0.004978179931640625, -0.0062713623046875, 0.01290130615234375, 0.01678466796875, -0.0020885467529296875, -0.017822265625, -0.01157379150390625, 0.0005407333374023438, 7.528066635131836e-05, 0.00025081634521484375, -0.0267791748046875, -0.0299072265625, -0.005161285400390625, -0.0096588134765625, -0.0074462890625, -0.004520416259765625, -0.004085540771484375, 0.0183563232421875, -0.00586700439453125, -0.0040283203125, -0.00562286376953125, -0.00746917724609375, -0.0080108642578125, 0.004222869873046875, 0.01306915283203125, -0.01593017578125, -0.00911712646484375, -0.0020580291748046875, 0.01058197021484375, 0.0172882080078125, -0.002124786376953125, 0.0182952880859375, -0.0207672119140625, 0.01085662841796875, 0.0005507469177246094, -0.03424072265625, -0.04302978515625, 0.0194549560546875, -0.006061553955078125, 0.0230712890625, -0.007694244384765625, 0.0157470703125, -0.0221099853515625, -0.0256500244140625, -0.00848388671875, -0.019744873046875, -0.00298309326171875, -0.0205841064453125, 0.0024585723876953125, -0.0028629302978515625, 0.0258026123046875, 0.006328582763671875, 0.003162384033203125, 0.0016002655029296875, 0.0102081298828125, 0.00039458274841308594, 0.0100555419921875, -0.0083770751953125, 0.004871368408203125, 0.009063720703125, -0.005786895751953125, 0.01544189453125, -0.004985809326171875, -0.0034351348876953125, 0.01244354248046875, -0.001995086669921875, 0.0208740234375, -0.006671905517578125, -0.01390838623046875, 0.0131988525390625, -0.022613525390625, -0.006011962890625, 0.0217132568359375, 0.031585693359375, -0.0017461776733398438, -0.01351165771484375, -0.002178192138671875, 0.0002727508544921875, -0.02423095703125, -0.029144287109375, -0.0086212158203125, -0.022430419921875, 0.00536346435546875, 0.007320404052734375, 0.00971221923828125, -0.0010814666748046875, -0.0162353515625, -0.01181793212890625, 0.022186279296875, -0.0110015869140625, -0.005680084228515625, 0.0088348388671875, 0.002834320068359375, -0.0030612945556640625, 0.0042877197265625, 0.0235137939453125, 0.01556396484375, 0.0014019012451171875, -0.01424407958984375, -0.003543853759765625, 0.003936767578125, 0.035369873046875, 0.001209259033203125, 0.004116058349609375, -0.05010986328125, -0.00394439697265625, 0.009735107421875, -0.0196075439453125, -0.00614166259765625, -0.01496124267578125, 0.002002716064453125, 0.01375579833984375, 0.01178741455078125, 0.00817108154296875, 0.0264739990234375, 0.01678466796875, -0.003387451171875, 0.01001739501953125, -0.01351165771484375, 0.007904052734375, -0.01541900634765625, 0.007091522216796875, 0.032196044921875, 0.0069122314453125, -0.0236968994140625, 0.0214996337890625, 0.0102691650390625, 0.007843017578125, -0.0292816162109375, -0.03826904296875, -0.0242919921875, -0.04534912109375, -0.0031414031982421875, 0.01035308837890625, 7.277727127075195e-05, 0.00988006591796875, -0.0268402099609375, 0.0255584716796875, 0.0311279296875, 0.023956298828125, -0.0172271728515625, 0.005462646484375, -0.025299072265625, -0.01300048828125, 0.0003101825714111328, 0.007007598876953125, -0.0137176513671875, -0.01099395751953125, -0.0296173095703125, -0.0027008056640625, 0.006946563720703125, 0.01322174072265625, -0.0081634521484375, 0.0114288330078125, -0.001708984375, -0.0083465576171875, -0.00690460205078125, -0.01068878173828125, -0.01451873779296875, 0.0140533447265625, 0.0060272216796875, -0.015960693359375, -0.0006556510925292969, 0.0229644775390625, -0.0026607513427734375, 0.0023860931396484375, 0.0098114013671875, -0.00414276123046875, 0.0018463134765625, 0.001880645751953125, 0.0111541748046875, 0.023529052734375, 0.0023441314697265625, -0.01479339599609375, 0.01177978515625, -0.0005841255187988281, -0.00914764404296875, -0.0015153884887695312, 0.00513458251953125, 0.00042819976806640625, 0.0013532638549804688, 0.006481170654296875, 0.00020003318786621094, -0.0099334716796875, -0.0218658447265625, 0.01367950439453125, -0.006755828857421875, 0.0186004638671875, -0.0014429092407226562, -0.0034389495849609375, -0.020050048828125, 0.0034313201904296875, -0.0302886962890625, 0.0026874542236328125, 0.006313323974609375, -0.00945281982421875, 0.0086212158203125, 0.0054931640625, 0.019378662109375, -0.001529693603515625, 0.025054931640625, 0.028411865234375, -0.0178375244140625, 7.212162017822266e-05, 0.007678985595703125, -0.0133209228515625, -0.00023698806762695312, 0.00984954833984375, 0.005275726318359375, -0.006412506103515625, -0.0012464523315429688, -0.003299713134765625, -0.005008697509765625, 0.0200347900390625, -0.003185272216796875, -0.0012054443359375, -0.0136566162109375, 0.00952911376953125, -0.038055419921875, 0.01544189453125, 0.00449371337890625, -0.01375579833984375, -0.01277923583984375, 0.0240631103515625, -0.028076171875, -0.01352691650390625, -0.01074981689453125, -0.0147705078125, -0.0020122528076171875, -0.005474090576171875, 0.023956298828125, -0.0015926361083984375, -0.0088653564453125, -0.037689208984375, -0.01120758056640625, 0.0200347900390625, -0.01419830322265625, -0.004161834716796875, 0.0139312744140625, -0.001708984375, -0.007843017578125, 0.044281005859375, -0.055633544921875, -0.0258941650390625, -0.0041046142578125, -0.005008697509765625, 0.03631591796875, 0.00046944618225097656, -0.0281982421875, -0.00232696533203125, 0.025604248046875, -0.0096893310546875, 0.0246429443359375, -0.0006856918334960938, 0.0006508827209472656, -0.01311492919921875, -0.01509857177734375, 0.0158233642578125, 0.0032825469970703125, -0.0168304443359375, -0.028106689453125, 0.0177001953125, -0.050750732421875, 0.03594970703125, -0.029144287109375, 0.0101165771484375, -0.0006628036499023438, 0.0002601146697998047, -0.000553131103515625, -0.0005083084106445312, 0.005779266357421875, 0.0063018798828125, -0.002902984619140625, 0.002162933349609375, -0.0170135498046875, -0.0040130615234375, -0.0022296905517578125, -0.01641845703125, 0.023406982421875, -0.00884246826171875, 0.01514434814453125, -0.0248870849609375, -0.02880859375, 0.0129241943359375, -0.01067352294921875, -0.00909423828125, -0.002285003662109375, -0.0017299652099609375, 0.025970458984375, 0.005245208740234375, 0.01401519775390625, 0.0175018310546875, -0.0089263916015625, -0.00646209716796875, -0.00229644775390625, -0.00481414794921875, 0.002040863037109375, -0.00872039794921875, 0.00640106201171875, 0.0034236907958984375, -0.0012712478637695312, -0.011688232421875, -0.0080108642578125, 0.0157928466796875, -0.004207611083984375, 0.0014772415161132812, -0.00861358642578125, 0.0118865966796875, 0.0137176513671875, -0.00298309326171875, 0.01340484619140625, -0.002429962158203125, 0.02520751953125, 0.015167236328125, 0.00861358642578125, -0.012237548828125, -0.06353759765625, 0.005580902099609375, 0.0023174285888671875, -0.00606536865234375, 0.005985260009765625, -0.03448486328125, 0.00762176513671875, 0.00891876220703125, 0.0110015869140625, 0.0008392333984375, 0.00397491455078125, -0.01568603515625, 0.0251312255859375, 0.00893402099609375, 0.00414276123046875, -0.015716552734375, 0.0199737548828125, -0.017059326171875, 0.00360870361328125, 0.0014314651489257812, -0.01058197021484375, -0.007537841796875, -0.0197906494140625, 0.0129852294921875, 0.0152740478515625, -0.01403045654296875, 0.01873779296875, 0.0274810791015625, -0.0081329345703125, -0.01039886474609375, 0.0107879638671875, 0.03961181640625, -0.0013895034790039062, -0.0040740966796875, -0.0268096923828125, -0.035858154296875, -0.0222930908203125, 0.01485443115234375, 0.0004868507385253906, 0.006710052490234375, -0.00980377197265625, 0.0138397216796875, 0.01873779296875, 0.0198516845703125, 0.01027679443359375, 0.0235748291015625, -0.006683349609375, -0.0221710205078125, -0.016998291015625, 0.00408935546875, -0.005634307861328125, 0.01151275634765625, 0.00441741943359375, -0.00679779052734375, 0.0039005279541015625, -0.007457733154296875, 0.0029315948486328125, 0.0202178955078125, -0.0011758804321289062, -0.009674072265625, -0.00426483154296875, -0.00443267822265625, -0.0025653839111328125, -0.0062713623046875, 0.0141143798828125, 0.01288604736328125, -0.0153961181640625, 0.00807952880859375, 0.01560211181640625, 0.0230865478515625, 0.0224151611328125, 0.017364501953125, -0.00567626953125, -0.0075531005859375, -0.021942138671875, -0.002750396728515625, 0.00872802734375, -0.0203399658203125, 0.024444580078125, -0.012603759765625, 0.022918701171875, 0.0113372802734375, 0.0085601806640625, -0.0087127685546875, -0.007415771484375, 0.0245361328125, 0.00909423828125, -0.002094268798828125, 0.0211029052734375, 0.01108551025390625, 0.0041961669921875, -0.033782958984375, 0.001445770263671875, 0.00838470458984375, 0.0069732666015625, -0.0251312255859375, -0.01001739501953125, 0.007099151611328125, 0.0286102294921875, -0.03399658203125, -0.01313018798828125, -0.0268402099609375, 0.0010709762573242188, -0.00904083251953125, -0.0095977783203125, -0.0015087127685546875, 0.00473785400390625, 0.0256500244140625, -0.00443267822265625, -0.0034046173095703125, -0.00998687744140625, -0.0076141357421875, -0.01556396484375, 0.0178985595703125, 0.01849365234375, 0.00701904296875, 0.0273590087890625, 0.001880645751953125, -0.0019502639770507812, 0.0007138252258300781, -0.01169586181640625, -0.00646209716796875, -0.007381439208984375, 0.0218353271484375, -0.0016002655029296875, 0.0010986328125, 0.0308685302734375, 0.0048065185546875, 0.00688934326171875, -0.004192352294921875, 0.0101318359375, -0.025054931640625, 0.0029239654541015625, -0.0210418701171875, 0.0060882568359375, -0.029449462890625, 0.0001697540283203125, 0.0166473388671875, 0.025482177734375, -0.018341064453125, -0.0131683349609375, -0.00103759765625, 0.0039520263671875, -0.0021190643310546875, 0.0175628662109375, 0.014678955078125, -0.00402069091796875, -0.01282501220703125, 0.0006170272827148438, 0.0030231475830078125, -0.0011148452758789062, -0.01082611083984375, 0.004474639892578125, -0.003215789794921875, -0.0018901824951171875, 0.0022602081298828125, -0.0007143020629882812, 0.004520416259765625, -0.0174560546875, 0.014434814453125, 0.0174560546875, -0.01554107666015625, 0.0179595947265625, 0.006977081298828125, -0.006221771240234375, -0.006816864013671875, -0.024139404296875, 0.022064208984375, -0.01358795166015625, -0.004364013671875, 0.006984710693359375, 0.008453369140625, -0.006191253662109375, -0.005619049072265625, 0.001979827880859375, -0.00801849365234375, -0.00946807861328125, -0.017669677734375, -0.0207672119140625, -0.00904083251953125, -0.0015735626220703125, 0.01369476318359375, -0.0188446044921875, 0.01335906982421875, -0.010498046875, -0.01105499267578125, -0.0119476318359375, 0.029754638671875, 0.0204315185546875, 0.007843017578125, -0.017059326171875, 0.0176239013671875, 0.0002906322479248047, 0.0126495361328125, 0.017608642578125, 0.026092529296875, -0.017242431640625, -0.0017881393432617188, 0.0054779052734375, 0.0024967193603515625, -0.00939178466796875, -0.0017518997192382812, -0.001750946044921875, -0.005466461181640625, -0.0438232421875, 0.022247314453125, -0.01085662841796875, 0.0157470703125, -0.003875732421875, -0.00147247314453125, 0.006282806396484375, -0.01434326171875, -0.0214080810546875, -0.0283050537109375, -0.0010442733764648438, -0.00824737548828125, -0.01403045654296875, 0.015655517578125, 0.027740478515625, 0.00926971435546875, -0.0004699230194091797, 0.0121002197265625, -0.0159912109375, 0.0211029052734375, 0.0098724365234375, 0.01090240478515625, 0.01250457763671875, -0.0016632080078125, 0.0225372314453125, 0.0023555755615234375, 0.00742340087890625, 0.01151275634765625, 0.002124786376953125, 0.0110626220703125, -0.007904052734375, -0.01163482666015625, -0.0086212158203125, -0.0080108642578125, -0.0186614990234375, 0.00362396240234375, -0.0014553070068359375, -0.0058746337890625, -0.033050537109375, -0.0123748779296875, 0.0181884765625, 0.03033447265625, -0.0202178955078125, 0.0120086669921875, 0.017486572265625, 0.049774169921875, 0.0010166168212890625, 0.01416015625, 0.0158538818359375, 0.0017652511596679688, -0.003849029541015625, -0.01256561279296875, -0.01071929931640625, 0.040069580078125, -0.0086822509765625, -0.01027679443359375, 0.0088043212890625, -0.002475738525390625, 0.0220489501953125, -0.00012111663818359375, 0.030548095703125, -0.0026035308837890625, 0.00844573974609375, 0.0419921875, -0.0188446044921875, 0.01361846923828125, -0.012542724609375, 0.01035308837890625, 0.053009033203125, -0.0200653076171875, 0.0007982254028320312, -0.0019216537475585938, 0.020355224609375, 0.0059967041015625, 0.008209228515625, 0.0187225341796875, 0.0159912109375, 0.00566864013671875, 0.00875091552734375, 0.0228424072265625, 0.007457733154296875, 0.0129852294921875, -0.023468017578125, -0.002880096435546875, 0.0240325927734375, 0.0146026611328125, -0.01543426513671875, 0.019195556640625, 0.0301971435546875, 0.0243682861328125, 0.01580810546875, 0.0094146728515625, 0.00743865966796875, -0.0074462890625, 0.006893157958984375, -0.0017728805541992188, 0.01739501953125, -0.0033626556396484375, 0.0033245086669921875, -0.006946563720703125, 0.004180908203125, -0.01131439208984375, -0.026641845703125, -0.006809234619140625, -0.0333251953125, 0.00342559814453125, -0.01078033447265625, 0.043701171875, 0.0146636962890625, 0.00481414794921875, -0.0013904571533203125, -0.04974365234375, -0.00933074951171875, -0.005680084228515625, 0.0018177032470703125, 0.004535675048828125, 0.01092529296875, 0.016143798828125, -0.01284027099609375, 0.0163421630859375, -0.03387451171875, -0.01214599609375, 0.013427734375, 0.0083465576171875, -0.0183563232421875, 0.00998687744140625, 0.001033782958984375, -0.029876708984375, -0.037261962890625, -0.018280029296875, 0.002765655517578125, -0.0167083740234375, -0.01000213623046875, -0.00139617919921875, 0.01212310791015625, 0.01175689697265625, 0.001041412353515625, 0.00897979736328125, 0.00881195068359375, 0.00995635986328125, 0.01493072509765625, -0.006641387939453125, -0.00626373291015625, -0.0254364013671875, 0.024444580078125, 0.01531219482421875, 0.006420135498046875, -0.0035190582275390625, -0.025604248046875, 0.026947021484375, 0.01424407958984375, 0.0200042724609375, -0.0135498046875, 0.031585693359375, -0.00666046142578125, -0.0175628662109375, 0.007904052734375, 0.01522064208984375, -0.0006780624389648438, 0.0166015625, -0.0165863037109375, 0.0165863037109375, -0.0015811920166015625, -0.0221405029296875, 0.0155181884765625, -0.01503753662109375, 0.0024967193603515625, -0.004299163818359375, -0.008636474609375, -0.024871826171875, 0.029022216796875, 0.008331298828125, 0.008575439453125, -0.0025806427001953125, -0.01335906982421875, -0.00817108154296875, -0.0966796875, -0.017913818359375, -0.017120361328125, 0.00945281982421875, 0.032684326171875, -0.01519012451171875, -0.0284881591796875, 0.007720947265625, 0.0211944580078125, -0.0214385986328125, -0.0186004638671875, 0.0124359130859375, -0.0190277099609375, -0.00791168212890625, 0.011260986328125, -0.0244140625, -0.013763427734375, -0.033905029296875, 0.00446319580078125, -0.007099151611328125, -0.025604248046875, 0.01068878173828125, -0.0213470458984375, -0.01073455810546875, -0.00235748291015625, 0.0086669921875, -0.0215606689453125, -0.0016832351684570312, -0.0090789794921875, -0.004119873046875, -0.0210113525390625, 0.012542724609375, 0.0118255615234375, 0.0013494491577148438, -0.006282806396484375, 0.0013408660888671875, -0.004634857177734375, -0.0055999755859375, -0.00485992431640625, -0.0007982254028320312, -0.0016002655029296875, 0.0164337158203125, 0.0125885009765625, -0.03826904296875, -0.000701904296875, -0.0013751983642578125, 0.0018243789672851562, -0.0343017578125, -0.01091766357421875, -0.00860595703125, -0.008148193359375, 0.0185546875, 0.0164337158203125, -0.0251312255859375, -0.00443267822265625, -0.0009756088256835938, -0.017578125, 0.0207977294921875, -0.025848388671875, 0.0100860595703125, -0.0107879638671875, -0.0113677978515625, -0.0149993896484375, -0.0232696533203125, 0.0189056396484375, -0.00045037269592285156, 0.002605438232421875, -0.004192352294921875, 0.01244354248046875, -0.005786895751953125, 0.0164031982421875, -0.01153564453125, -0.0209503173828125, 0.003875732421875, -0.01023101806640625, -0.007122039794921875, 0.0164031982421875, 0.00762176513671875, -0.034912109375, -0.0081024169921875, 0.01087188720703125, 0.00139617919921875, -0.0118560791015625, 0.01355743408203125, -0.005138397216796875, 0.0017309188842773438, 0.0345458984375, 0.0038909912109375, -0.0030307769775390625, -0.0211029052734375, -0.0295867919921875, -0.004180908203125, 0.018798828125, 0.0179290771484375, -0.0214385986328125, -0.0019140243530273438, -0.0117034912109375, 0.0118255615234375, 0.0200958251953125, 0.007694244384765625, 0.003330230712890625, 0.01334381103515625, 0.0271759033203125, -0.005710601806640625, -0.024017333984375, -0.0084228515625, -0.015625, -0.00746917724609375, 0.007049560546875, 0.0114288330078125, -0.0004582405090332031, -0.01369476318359375, 0.0244140625, -0.0271453857421875, 0.02276611328125, 0.007579803466796875, 0.00434112548828125, 0.0093536376953125, 0.0240631103515625, -0.01145172119140625, -0.00649261474609375, -0.0144500732421875, 0.00838470458984375, 0.0250091552734375, -0.001224517822265625, 0.006805419921875, -0.022735595703125, -0.006526947021484375, 0.03369140625, 0.0022735595703125, 0.0113983154296875, 0.003597259521484375, 0.01953125, 0.0099639892578125, 0.017242431640625, -0.009002685546875, 0.01288604736328125, 0.0026493072509765625, 0.004779815673828125, -0.00295257568359375, 0.0006403923034667969, 0.004589080810546875, 0.0174560546875, 0.00545501708984375, 0.0162811279296875, 0.0083160400390625, -0.01424407958984375, -0.0006766319274902344, 0.01329803466796875, 0.023590087890625, 0.0010347366333007812, 0.0008263587951660156, -0.0054168701171875, -0.0021038055419921875, -0.00196075439453125, -0.0311279296875, 0.001834869384765625, 0.01212310791015625, -0.0178070068359375, -0.033905029296875, 0.007717132568359375, -0.0192108154296875, 0.019134521484375, 0.00714111328125, -0.01445770263671875, 0.0036029815673828125, 0.026092529296875, -0.01751708984375, -0.0087432861328125, 0.0218353271484375, -0.01395416259765625, -0.00765228271484375, -0.0094146728515625, -0.016021728515625, 0.002140045166015625, 0.01953125, 0.0027923583984375, -0.0147247314453125, 0.00579071044921875, -0.0028934478759765625, -0.0235748291015625, -0.032928466796875, 0.0012531280517578125, 0.0054473876953125, 0.0138397216796875, -0.006000518798828125, -0.0026035308837890625, -0.005336761474609375, -0.019134521484375, 0.00548553466796875, 0.00150299072265625, 0.006011962890625, -0.0031642913818359375, -0.01328277587890625, -0.0120391845703125, 0.004825592041015625, 0.023193359375, -0.0163421630859375, 0.02032470703125, 0.0022258758544921875, 0.019439697265625, 0.003826141357421875, -0.0182342529296875, -0.0467529296875, -0.012237548828125, 0.005832672119140625, 0.00397491455078125, -0.0019063949584960938, -0.0005273818969726562, -0.023834228515625, -0.01560211181640625, -0.0028209686279296875, -0.003192901611328125, -0.03826904296875, 0.0125885009765625, -0.0018777847290039062, -0.0190277099609375, -0.0004925727844238281, 0.005519866943359375, 0.00952911376953125, 0.0081024169921875, 0.0178375244140625, -0.0347900390625, 0.014495849609375, -0.0131683349609375, -0.01145172119140625, 0.003177642822265625, -0.01380157470703125, 0.01403045654296875, -0.0247650146484375, 0.0218353271484375, 0.01027679443359375, -0.004756927490234375, 0.01531219482421875, 0.01294708251953125, 0.0212249755859375, 0.0036487579345703125, 0.0207366943359375, -0.0041656494140625, 0.0115203857421875, 0.01345062255859375, -0.005908966064453125, -0.007965087890625, -0.01409149169921875, 0.0048980712890625, -0.00209808349609375, -0.0160980224609375, -0.0096282958984375, -0.0016756057739257812, 0.0278472900390625, -0.0247650146484375, 0.0103302001953125, -0.006473541259765625, -0.00665283203125, 0.0003077983856201172, -0.0149993896484375, -0.031463623046875, -0.0034885406494140625, 0.0010623931884765625, 0.0982666015625, 0.00565338134765625, 0.0118865966796875, 0.007091522216796875, -0.027740478515625, -0.0093536376953125, 0.0260162353515625, -0.0185394287109375, -0.0011682510375976562, -0.02587890625, -0.0176849365234375, 0.01129150390625, -0.0016469955444335938, 0.0261383056640625, -0.02520751953125, -0.0307159423828125, 0.0032634735107421875, 0.0013513565063476562, 0.0020694732666015625, 0.017669677734375, 0.006412506103515625, -0.019256591796875, -0.002452850341796875, -0.0016698837280273438, -0.0006818771362304688, 0.001560211181640625, -0.01080322265625, -0.007965087890625, -0.0043792724609375, 0.00914764404296875, -0.038177490234375, 0.0164031982421875, -0.00414276123046875, 0.01004791259765625, 0.006175994873046875, 0.00021541118621826172, 0.005123138427734375, 0.00710296630859375, -0.017547607421875, 0.01351165771484375, -0.01334381103515625, 0.01544189453125, -0.047149658203125, 0.0022411346435546875, 0.02166748046875, 0.0113983154296875, -0.0188140869140625, 0.0029926300048828125, 0.0010166168212890625, -0.0110015869140625, 0.0012531280517578125, -1.4185905456542969e-05, -0.00807952880859375, -0.0108795166015625, 0.01580810546875, 0.00568389892578125, -0.00148773193359375, 0.0222015380859375, -0.0211029052734375, 0.014556884765625, -0.01003265380859375, 0.002429962158203125, 0.00482177734375, -0.006412506103515625, 0.013946533203125, 0.0229034423828125, 0.006191253662109375, 0.01294708251953125, 0.0233917236328125, -0.023895263671875, 0.0276031494140625, -0.031646728515625, 0.0045623779296875, 0.00476837158203125, 0.0035228729248046875, -0.026611328125, -0.01244354248046875, -0.026641845703125, 0.004253387451171875, 0.0038909912109375, -0.01041412353515625, -0.0033969879150390625, 0.0161590576171875, -0.00019299983978271484, 0.035247802734375, -0.00930023193359375, -0.01544189453125, 0.03350830078125, 0.01058197021484375, 0.0167083740234375, 0.006877899169921875, 0.00998687744140625, -0.00482940673828125, -0.00911712646484375, 0.0108489990234375, -0.01007080078125, -0.007061004638671875, -0.0300750732421875, 0.016204833984375, 0.00669097900390625, -0.0214385986328125, -0.0322265625, -0.0190887451171875, 0.0125274658203125, 0.02685546875, 0.0179443359375, 0.01415252685546875, 0.00632476806640625, 0.017120361328125, -0.005046844482421875, 0.004306793212890625, -0.0282745361328125, -0.0095977783203125, 0.01425933837890625, -0.001018524169921875, 0.0096282958984375, 0.00556182861328125, 0.017181396484375, 0.01300048828125, 0.0184783935546875, 0.001743316650390625, -0.0186920166015625, 0.0006284713745117188, 0.006420135498046875, -0.00749969482421875, -0.018524169921875, -0.0114593505859375, -0.007663726806640625, 0.0299072265625, -0.01169586181640625, 0.0018558502197265625, -0.0096893310546875, 0.00463104248046875, -0.0033721923828125, 0.01141357421875, -0.03692626953125, 0.005298614501953125, 0.004528045654296875, 0.0300750732421875, -0.026519775390625, -0.01522064208984375, -0.00513458251953125, -0.03741455078125, 0.0165863037109375, -0.0232391357421875, -0.00460052490234375, 0.0214385986328125, -0.00780487060546875, 0.0012273788452148438, 0.003276824951171875, -0.0161590576171875, 0.0013380050659179688, 0.005374908447265625, -0.011993408203125, 0.012054443359375, -0.01513671875, 0.0180206298828125, 0.03179931640625, 0.0010595321655273438, 0.0149078369140625, -0.0198516845703125, 0.008148193359375, -0.008026123046875, -0.03759765625, 0.009124755859375, -0.0106964111328125, -0.0025310516357421875, 0.0072479248046875, 0.01611328125, 0.00818634033203125, 0.020660400390625, -0.004726409912109375, 0.022369384765625, -0.006923675537109375, 2.9325485229492188e-05, -0.015167236328125, 0.015625, -0.0009226799011230469, -0.006679534912109375, 0.01215362548828125, 0.00579071044921875, 0.0018568038940429688, -0.0102691650390625, -0.0128631591796875, 0.009765625, 0.010467529296875, -0.00763702392578125, 0.039459228515625, 0.00811004638671875, 0.017547607421875, 0.043426513671875, -0.0338134765625, 0.0081024169921875, -0.0012378692626953125, -0.0215301513671875, 0.031982421875, -0.0025043487548828125, 0.002918243408203125, 0.019927978515625, -0.022796630859375, 0.0157470703125, 0.00820159912109375, -0.006412506103515625, 0.0499267578125, -0.0059661865234375, -0.017852783203125, -0.0029964447021484375, -0.0108489990234375, -0.009246826171875, 0.007747650146484375, -0.0018358230590820312, -0.017791748046875, -0.0220794677734375, -0.0229034423828125, 0.0013713836669921875, -0.00847625732421875, 0.01470184326171875, -0.006412506103515625, -0.01541900634765625, 0.0191650390625, 0.004840850830078125, -0.01202392578125, 0.0244293212890625, 0.03057861328125, 0.013763427734375, -0.00765228271484375, 0.00786590576171875, 0.018829345703125, 0.01338958740234375, 0.029693603515625, -0.007266998291015625, -0.002887725830078125, 0.01495361328125, 0.0004992485046386719, -0.005397796630859375, -0.0102081298828125, 0.017242431640625, 0.0121002197265625, 0.0253143310546875, 0.007541656494140625, -0.01181793212890625, -0.007663726806640625, 0.0072174072265625, -0.0235137939453125, 0.005359649658203125, -0.00930023193359375, 0.01081085205078125, 0.0184783935546875, -0.004177093505859375, 0.0210723876953125, -0.007495880126953125, -0.00775146484375, -0.05535888671875, 0.0078125, 0.01090240478515625, 0.024749755859375, -0.0099334716796875, -0.0165252685546875, -0.00930023193359375, -0.00048089027404785156, 0.040740966796875, 0.0200958251953125, -0.001827239990234375, 0.0083465576171875, -0.00347137451171875, -0.0079345703125, -0.006313323974609375, -0.0081787109375, -0.0192108154296875, 0.0020503997802734375, 0.031158447265625, 0.0007543563842773438, -0.01006317138671875, 0.0148468017578125, 0.002292633056640625, -0.03875732421875, -0.0001823902130126953, -0.015869140625, -0.0142364501953125, -0.005218505859375, -0.002147674560546875, -0.0131072998046875, -0.0179443359375, -0.0158538818359375, 0.00640106201171875, -0.0007290840148925781, 0.01378631591796875, 0.003875732421875, -0.00481414794921875, 0.01277923583984375, -0.0101470947265625, -0.0202789306640625, 0.02789306640625, 0.016143798828125, 0.01050567626953125, 0.00597381591796875, 0.0006914138793945312, 0.0005540847778320312, 0.004863739013671875, 0.01238250732421875, 0.0247650146484375, -0.007843017578125, -0.018280029296875, 0.01532745361328125, 0.01250457763671875, -0.00998687744140625, 0.0091400146484375, 0.0236968994140625, -0.021942138671875, 0.0027065277099609375, 0.018157958984375, 0.0026092529296875, -0.0008311271667480469, 0.02734375, 0.0162811279296875, -0.01256561279296875, 0.00623321533203125, -0.0186920166015625, -0.0095672607421875, -0.03521728515625, 0.0208740234375, 0.00348663330078125, -0.0196990966796875, 0.01294708251953125, -0.0079498291015625, -0.0275115966796875, -0.004589080810546875, -0.0182342529296875, 0.01262664794921875, -0.0014467239379882812, -0.003753662109375, 0.01271820068359375, -0.019256591796875, 0.0269775390625, -0.00986480712890625, -0.01067352294921875, -0.023895263671875, 0.00942230224609375, -0.0236968994140625, 0.020172119140625, 0.0001418590545654297, -0.0033721923828125, -0.014068603515625, -0.0137786865234375, 0.014495849609375, 0.00481414794921875, 0.0022716522216796875, 0.004608154296875, -0.0212249755859375, 0.0162200927734375, -0.0013828277587890625, -0.004573822021484375, -0.01340484619140625, 0.0205841064453125, -0.005542755126953125, -0.04498291015625, 7.152557373046875e-05, -0.01071929931640625, -0.0100250244140625, -0.0085296630859375, -0.016693115234375, 0.01215362548828125, 0.0108184814453125, -0.0017490386962890625, -0.0015583038330078125, 0.00942230224609375, -0.037811279296875, 0.00679779052734375, -0.01024627685546875, -0.01067352294921875, 0.007007598876953125, 0.0213775634765625, -0.0059356689453125, -0.01006317138671875, 0.01058197021484375, 0.01690673828125, -0.01235198974609375, -0.004302978515625, 0.00292205810546875, -0.01142120361328125, -0.018890380859375, 0.01284027099609375, -0.01513671875, 0.0183563232421875, 0.0038166046142578125, -0.0006113052368164062, -0.004077911376953125, -0.0179290771484375, -0.0277862548828125, 0.005260467529296875, -0.00952911376953125, 0.01116943359375, -0.01085662841796875, -0.00640106201171875, 0.0124664306640625, 0.023529052734375, -0.0140533447265625, -0.0073394775390625, -0.00513458251953125, -0.00984954833984375, 0.003570556640625, -0.022918701171875, 0.0133209228515625, -0.05242919921875, 0.01666259765625, 0.009063720703125, 0.029876708984375, -0.01495361328125, 0.00832366943359375, 0.02386474609375, -0.02874755859375, -0.014739990234375, 0.006221771240234375, -0.0084991455078125, -0.006679534912109375, 0.0016317367553710938, 0.009124755859375, -0.002132415771484375, -0.0007700920104980469, -0.01415252685546875, 0.021331787109375, 0.016143798828125, -0.011871337890625, 0.005397796630859375, 0.0018777847290039062, 0.016754150390625, -0.003360748291015625, -0.024017333984375, -0.0026531219482421875, 0.01419830322265625, -0.010467529296875, 0.004039764404296875, -0.017791748046875, 0.0011854171752929688, 0.01294708251953125, -0.015960693359375, -0.0038471221923828125, -0.01503753662109375, 0.0100250244140625, -0.007579803466796875, -0.00392913818359375, 0.0009927749633789062, -0.025299072265625, 0.01369476318359375, -0.0008668899536132812, -0.0165863037109375, 0.002368927001953125, 0.0009002685546875, -0.004180908203125, -0.0034732818603515625, 0.009765625, 0.0168304443359375, -0.007259368896484375, 2.1755695343017578e-05, -0.007678985595703125, 0.0009021759033203125, -0.0004410743713378906, 0.00015091896057128906, 0.0032558441162109375, -0.00472259521484375, -0.005474090576171875, -0.0183563232421875, -0.00937652587890625, -0.0014734268188476562, -0.003345489501953125, 0.0245819091796875, 0.003993988037109375, 0.01244354248046875, -0.006221771240234375, -0.042205810546875, -0.0186767578125, 0.003215789794921875, -0.031585693359375, 0.0131072998046875, 0.02166748046875, -0.0038738250732421875, -0.00902557373046875, -0.006076812744140625, -0.0159149169921875, -0.0147705078125, 0.00945281982421875, -0.006359100341796875, -0.0237579345703125, -0.0185394287109375, 0.00897216796875, -0.0101470947265625, 0.002300262451171875, 0.0008783340454101562, 0.0024261474609375, -0.0158843994140625, 0.017242431640625, -0.037322998046875, -0.022552490234375, 0.0116729736328125, -0.0183563232421875, 0.027618408203125, 0.005367279052734375, -0.0060272216796875, -0.04583740234375, 0.02374267578125, -0.01024627685546875, 0.01043701171875, 0.005878448486328125, 0.01116180419921875, 0.0350341796875, 0.0038433074951171875, 0.0318603515625, 0.004589080810546875, 0.031982421875, 0.01004791259765625, 0.0229644775390625, 0.002742767333984375, 0.0006608963012695312, -0.0164642333984375, -0.039398193359375, 0.0096282958984375, 1.5676021575927734e-05, 0.00914764404296875, -0.0289764404296875, -0.00649261474609375, -0.0007176399230957031, -0.0238037109375, 0.0015077590942382812, -0.00437164306640625, 0.01235198974609375, 0.0168304443359375, -0.01070404052734375, 0.0130462646484375, -0.0145721435546875, -0.005710601806640625, 0.00811004638671875, -0.0196990966796875, 0.0052490234375, -0.01302337646484375, -0.0031566619873046875, -0.032806396484375, -0.0190277099609375, -0.017303466796875, 0.0087738037109375, 0.018280029296875, -0.01605224609375, -0.01442718505859375, -0.0186920166015625, 0.01220703125, -0.00830078125, 0.005344390869140625, -0.0275115966796875, -0.0037403106689453125, 0.006412506103515625, -0.0419921875, 0.0231475830078125, 0.01525115966796875, -0.047393798828125, 0.013763427734375, 0.001979827880859375, -0.01007843017578125, 0.0028705596923828125, 0.01123809814453125, -0.01338958740234375, 0.0014142990112304688, 0.002017974853515625, 0.004955291748046875, -0.0097198486328125, 0.00928497314453125, -0.00807952880859375, -0.01081085205078125, -0.002620697021484375, 0.01384735107421875, -0.01464080810546875, -0.00426483154296875, 0.004314422607421875, -0.004306793212890625, -0.0075225830078125, 0.00428009033203125, -0.0148468017578125, 0.0246429443359375, 0.0019426345825195312, -0.0081024169921875, -0.0133056640625, -0.00821685791015625, -0.01432037353515625, 0.04742431640625, 0.0056915283203125, -0.00392913818359375, -0.0121917724609375, -0.01058197021484375, 0.004108428955078125, 0.0269775390625, 0.008941650390625, -0.0012559890747070312, 0.00830078125, 0.016632080078125, 0.0143280029296875, 0.001617431640625, -0.006744384765625, 0.0009698867797851562, -0.0013303756713867188, -0.008056640625, -0.00047588348388671875, -0.0111846923828125, 0.0230712890625, -0.0218505859375, -0.027008056640625, -0.0201568603515625, 0.03619384765625, -0.0159912109375, 0.002033233642578125, -0.0222625732421875, 0.0026454925537109375, 0.0031108856201171875, -0.005069732666015625, -0.002361297607421875, 0.01485443115234375, 0.009124755859375, 0.004489898681640625, 0.0013532638549804688, -0.0059051513671875, -0.000942230224609375, 0.022430419921875, -0.01300048828125, -0.01849365234375, 0.01386260986328125, 0.017730712890625, 0.007068634033203125, 0.01073455810546875, 0.031982421875, -0.00786590576171875, -0.003749847412109375, -0.00469970703125, -0.009368896484375, -0.015960693359375, 0.0052490234375, -0.004940032958984375, 0.0186614990234375, -0.026214599609375, -0.01361083984375, 0.017547607421875, -0.02099609375, 0.005859375, -0.000225067138671875, 0.0197601318359375, 0.01010894775390625, -0.01407623291015625, 0.018524169921875, -0.0008392333984375, -0.006191253662109375, -0.0030670166015625, -0.0026493072509765625, 0.036285400390625, 0.00917816162109375, 0.003078460693359375, -0.006343841552734375, 0.0007233619689941406, 0.0023708343505859375, 0.006671905517578125, 0.00936126708984375, -0.01348876953125, -0.01374053955078125, -0.0032405853271484375, -0.015838623046875, 0.019683837890625, 0.0192108154296875, 0.006725311279296875, -0.00513458251953125, 0.015716552734375, -0.01593017578125, -0.00533294677734375, 0.0024547576904296875, 0.004741668701171875, -0.0211029052734375, -0.0131988525390625, -0.003276824951171875, -0.00106048583984375, 0.003635406494140625, 0.006134033203125, -0.01436614990234375, -0.001995086669921875, 0.00115966796875, 0.01305389404296875, 0.013671875, -0.024810791015625, -0.005191802978515625, 0.00087738037109375, 0.00469207763671875, -0.0079345703125, -0.01238250732421875, 0.0001838207244873047, 0.0133209228515625, -0.009796142578125, -0.018096923828125, 0.006557464599609375, -0.00177001953125, 0.009246826171875, 0.0181732177734375, 0.00672149658203125, 0.0127410888671875, 0.0212249755859375, -0.01226806640625, -0.0191192626953125, 0.0164642333984375, -0.01593017578125, -0.0090484619140625, 0.003948211669921875, -0.00792694091796875, 0.0229644775390625, -0.01016998291015625, -0.0090789794921875, -0.0112457275390625, -0.00836181640625, -0.01338958740234375, 0.022308349609375, -0.0286865234375, -0.0150604248046875, -0.002475738525390625, -0.006870269775390625, -0.0129241943359375, 0.0033550262451171875, -0.0042266845703125, -0.00749969482421875, 0.0251312255859375, -0.005893707275390625, 0.00832366943359375, -0.0213470458984375, -0.0016574859619140625, 0.01480865478515625, -0.00991058349609375, 0.012176513671875, -0.0127105712890625, 0.0211944580078125, -0.0042572021484375, 0.0140380859375, -0.0266876220703125, 0.00344085693359375, 0.004756927490234375, 0.0016231536865234375, 0.002162933349609375, 0.0003485679626464844, -0.008514404296875, 0.0110015869140625, -0.0028820037841796875, -0.0271148681640625, 0.01474761962890625, -0.0267791748046875, -0.02178955078125, -0.00905609130859375, -0.00897216796875, 0.006175994873046875, 0.0107879638671875, -0.007415771484375, 0.045806884765625, 0.01262664794921875, 0.005054473876953125, -0.0204315185546875, -0.0011339187622070312, 0.0086517333984375, -0.0156097412109375, 0.0002448558807373047, -0.028900146484375, -0.0009331703186035156, -0.01375579833984375, 0.01380157470703125, -0.021820068359375, -0.01328277587890625, -0.01149749755859375, 0.01959228515625, -0.00789642333984375, 0.00820159912109375, 0.0097503662109375, 0.007549285888671875, 0.0171356201171875, -0.018829345703125, 0.0067138671875, -0.0125885009765625, -3.898143768310547e-05, 0.00927734375, 0.0135345458984375, 0.021270751953125, -0.0242919921875, 0.00018990039825439453, -0.0165863037109375, -0.0110626220703125, 0.0203704833984375, -0.0282440185546875, 0.041748046875, -0.005054473876953125, 0.00836181640625, 0.0005540847778320312, 0.017333984375, 0.0021114349365234375, 0.003459930419921875, -0.003810882568359375, -0.01113128662109375, -0.025543212890625, 0.002140045166015625, -0.0024967193603515625, -0.02099609375, -0.0142059326171875, 0.00048422813415527344, 0.01468658447265625, -0.0017232894897460938, -0.0007524490356445312, -0.0245361328125, -0.017669677734375, 0.02276611328125, -0.015960693359375, -0.0247039794921875, 0.04083251953125, 0.0089874267578125, -0.00014913082122802734, -0.0130462646484375, 0.014739990234375, 0.019866943359375, 0.00759124755859375, 0.022979736328125, 0.0125885009765625, 0.0221710205078125, 0.0180511474609375, -0.00954437255859375, -0.0090484619140625, -0.0029315948486328125, -0.00377655029296875, -0.0013895034790039062, -0.01262664794921875, 0.004451751708984375, -0.0088348388671875, 0.019317626953125, 0.032440185546875, -0.0013132095336914062, 0.043426513671875, -0.005130767822265625, 0.0093536376953125, -0.0025310516357421875, 0.030914306640625, 0.003997802734375, -0.01073455810546875, -0.00872802734375, -0.0101470947265625, 0.0175018310546875, 0.01526641845703125, -0.03961181640625, -0.011260986328125, 0.00951385498046875, -0.0233154296875, 0.0209503173828125, 0.011322021484375, -0.005443572998046875, -0.00013053417205810547, -0.0162811279296875, 0.0247039794921875, 0.01537322998046875, -0.01059722900390625, 0.014068603515625, 0.01361083984375, 0.030242919921875, -0.019927978515625, 0.0072021484375, 0.013885498046875, 0.01690673828125, 0.0099029541015625, -0.004894256591796875, 0.00408172607421875, -0.059234619140625, 0.005710601806640625, 0.0012712478637695312, 0.01256561279296875, -0.00528717041015625, 0.01094818115234375, -0.01459503173828125, -0.0200347900390625, -0.00844573974609375, 0.0017852783203125, -0.0024967193603515625, 0.007965087890625, -0.006587982177734375, 0.0294036865234375, -0.0253753662109375, 0.0133209228515625, 0.00502777099609375, 0.0007138252258300781, -0.0097198486328125, -0.01525115966796875, 0.01004791259765625, 0.0122833251953125, -0.0263519287109375, 0.0131683349609375, -0.00780487060546875, 0.010498046875, 0.0021820068359375, 0.0031795501708984375, -0.006443023681640625, -0.003917694091796875, 0.0034389495849609375, 0.01087188720703125, 0.007747650146484375, -0.01335906982421875, 0.007045745849609375, 0.0082550048828125, -0.0200653076171875, 0.004547119140625, -0.0269317626953125, 0.00763702392578125, 0.01043701171875, -0.005184173583984375, -0.0014553070068359375, -0.01058197021484375, 0.0086669921875, 0.006122589111328125, -0.01666259765625, 0.0215301513671875, 0.01076507568359375, -0.0165863037109375, -0.00417327880859375, -0.0085296630859375, -0.0027561187744140625, -0.006683349609375, 0.016387939453125, 0.01092529296875, 0.0036067962646484375, 0.007415771484375, 0.006076812744140625, -0.002044677734375, 0.00811004638671875, -0.0149383544921875, 0.025299072265625, 0.0024585723876953125, -0.00629425048828125, -0.02899169921875, -0.0010404586791992188, -0.01525115966796875, 0.0027370452880859375, -0.0160980224609375, -0.01256561279296875, -0.0015363693237304688, -0.0005397796630859375, 0.0160980224609375, -0.0299224853515625, 0.005443572998046875, -0.01073455810546875, -0.0155029296875, 0.02789306640625, 0.0131072998046875, -0.000835418701171875, -0.00887298583984375, 0.01187896728515625, 0.0016002655029296875, -0.004291534423828125, -0.0169525146484375, 0.0030956268310546875, 0.0087738037109375, 0.036468505859375, 0.00047397613525390625, -0.0025119781494140625, 0.01178741455078125, -0.00762176513671875, 0.00286102294921875, -0.0290679931640625, -0.01238250732421875, -8.237361907958984e-05, -0.03533935546875, 0.006072998046875, -0.003078460693359375, -0.0001742839813232422, 0.0002770423889160156, -0.01491546630859375, 0.018280029296875, 0.015655517578125, 0.0260162353515625, -0.01378631591796875, -0.04669189453125, -0.0026721954345703125, 0.00516510009765625, -0.01201629638671875, -0.03570556640625, 0.0142059326171875, 0.026214599609375, 0.02166748046875, -0.0009555816650390625, 0.00750732421875, 0.0178070068359375, 0.020355224609375, 0.0221099853515625, -0.000705718994140625, 0.0087432861328125, -0.0131683349609375, -0.03521728515625, 0.00493621826171875, 0.003818511962890625, 0.0325927734375, 0.0099639892578125, -0.016876220703125, 0.022674560546875, 0.00550079345703125, -0.01013946533203125, -0.00759124755859375, -0.0113983154296875, -0.00047659873962402344, 0.005908966064453125, -0.0045013427734375, -0.0031414031982421875, 0.0017223358154296875, 0.018707275390625, -0.00763702392578125, -0.0180206298828125, -0.00998687744140625, -0.002750396728515625, 0.0032711029052734375, 0.017669677734375, 0.00498199462890625, -0.0013494491577148438, -0.025604248046875, 0.0079193115234375, -0.0190277099609375, -0.00582122802734375, 0.00547027587890625, -0.05389404296875, -0.0215911865234375, -0.01464080810546875, 0.0009179115295410156, -0.01544189453125, -0.005191802978515625, 0.00548553466796875, -0.003780364990234375, -0.01071929931640625, 0.0014057159423828125, -0.003971099853515625, 0.01175689697265625, -0.00428009033203125, 0.020660400390625, 0.02410888671875, 0.0009388923645019531, 0.00984954833984375, -0.0013132095336914062, -0.0194244384765625, 0.0013856887817382812, 0.0003833770751953125, 0.053131103515625, -0.0004665851593017578, 0.011688232421875, -0.0197601318359375, 0.0182952880859375, -0.005519866943359375, -0.00658416748046875, -0.002773284912109375, -0.004993438720703125, -0.0212860107421875, 0.004302978515625, -0.0306549072265625, 0.01305389404296875, 0.00568389892578125, -0.0088043212890625, -0.0010728836059570312, -0.003997802734375, -0.01323699951171875, -0.0160980224609375, 0.0133056640625, 0.01128387451171875, 0.020782470703125, 0.0245819091796875, 0.015167236328125, 0.0265655517578125, 0.032928466796875, -0.01078033447265625, -0.0096435546875, -0.01776123046875, -0.005588531494140625, -0.0007314682006835938, 0.003108978271484375, -0.01357269287109375, 0.023773193359375, -0.0129852294921875, -0.0214691162109375, 0.002849578857421875, 0.019378662109375, -0.0260467529296875, -0.00897979736328125, 0.002079010009765625, 0.0208587646484375, -0.02777099609375, 0.005767822265625, -0.0238037109375, -0.0015783309936523438, -0.006565093994140625, 0.00567626953125, -0.011932373046875, -0.0181427001953125, -0.0106048583984375, -0.01119232177734375, 0.027099609375, 0.0258941650390625, 0.004364013671875, 0.0073394775390625, -0.01107025146484375, 0.0109405517578125, -0.00775146484375, -0.0081329345703125, -9.304285049438477e-05, -0.0002903938293457031, 0.021697998046875, -0.01367950439453125, -0.00043845176696777344, 0.004055023193359375, -0.008026123046875, -0.0085296630859375, -0.00992584228515625, 0.0008931159973144531, 0.0043182373046875, -0.004207611083984375, 0.0007562637329101562, 0.0113067626953125, -0.0128021240234375, -0.034027099609375, 0.007080078125, 0.01541900634765625, 0.0010213851928710938, 0.01061248779296875, -0.01157379150390625, -0.026336669921875, -0.002811431884765625, -0.01049041748046875, 0.0008993148803710938, 0.00835418701171875, 0.002849578857421875, -0.0014314651489257812, -0.0166473388671875, -0.01004791259765625, 0.00787353515625, -0.01522064208984375, -0.007694244384765625, 0.0125885009765625, -0.00943756103515625, 0.01690673828125, -0.008697509765625, -0.01052093505859375, 0.00522613525390625, -1.4841556549072266e-05, 0.0012722015380859375, 0.0029163360595703125, -0.005565643310546875, 0.0185699462890625, -0.005138397216796875, 0.0032100677490234375, 0.00312042236328125, -0.00739288330078125, 0.01116180419921875, -0.003719329833984375, 0.0116424560546875, 0.0147857666015625, 0.0238037109375, -0.01142120361328125, 0.0245361328125, -0.0208282470703125, -0.009185791015625, -0.007541656494140625, 0.02947998046875, 0.006134033203125, 0.0184173583984375, -0.0250091552734375, -0.00502777099609375, -0.007110595703125, 0.004543304443359375, 0.0153961181640625, 0.002223968505859375, -0.00012314319610595703, 0.007381439208984375, -0.009033203125, 0.023223876953125, 0.0287322998046875, -0.00677490234375, 0.0027637481689453125, 0.0021190643310546875, -0.0181884765625, 0.012939453125, -0.0133209228515625, -0.00927734375, -0.0148773193359375, -0.01262664794921875, 0.0127410888671875, 0.0073699951171875, 0.0037555694580078125, 0.05462646484375, 0.0080718994140625, 0.00482940673828125, 0.00878143310546875, -0.0253143310546875, -0.0207366943359375, -0.0165252685546875, -0.01142120361328125, -0.01605224609375, 0.00495147705078125, -0.005001068115234375, -0.0172271728515625, 0.01496124267578125, 0.032806396484375, 0.016143798828125, -0.0059356689453125, -0.0177459716796875, 0.00507354736328125, 0.00626373291015625, 0.0253143310546875, -0.00176239013671875, -0.00531768798828125, -0.006671905517578125, -0.0069427490234375, -0.0078582763671875, -0.025726318359375, -0.0054931640625, 0.0032253265380859375, 0.031280517578125, -0.019256591796875, -0.0087738037109375, -0.0214385986328125, -0.003833770751953125, 0.0078582763671875, -0.00930023193359375, -0.0018062591552734375, -0.00632476806640625, -0.006011962890625, 0.016510009765625, 0.0188446044921875, 0.005229949951171875, -0.0013360977172851562, -0.031982421875, -0.002208709716796875, 0.007770538330078125, -0.003131866455078125, 0.010833740234375, -0.00437164306640625, -0.024871826171875, 0.032745361328125, -0.022308349609375, 0.00152587890625, 0.031219482421875, -0.00907135009765625, 0.0186004638671875, -0.01093292236328125, 0.01485443115234375, -0.0264434814453125, 0.0217132568359375, 0.0085601806640625, -0.03680419921875, 0.0168914794921875, -0.0007929801940917969, -0.00016987323760986328, 0.01064300537109375, 0.000370025634765625, -0.0226287841796875, -0.007480621337890625, 0.0216827392578125, 0.007457733154296875, -0.0035305023193359375, 0.0099029541015625, -0.007843017578125, -0.0241241455078125, -0.0297088623046875, -0.004650115966796875, -0.03485107421875, -0.006587982177734375, -0.0068206787109375, -0.0036067962646484375, 0.01142120361328125, -0.0054168701171875, 0.005374908447265625, -0.0223236083984375, 0.024078369140625, 0.00408172607421875, 0.00626373291015625, -0.00640106201171875, -0.00969696044921875, 9.930133819580078e-05, -0.003200531005859375, -0.00875091552734375, 0.01165008544921875, -0.0127716064453125, -0.007610321044921875, 0.04632568359375, -0.0088348388671875, -0.01067352294921875, 0.01120758056640625, -0.00150299072265625, -0.004009246826171875, -0.0205230712890625, 0.018829345703125, -0.014434814453125, -0.0027370452880859375, -0.025543212890625, -0.00432586669921875, -0.032684326171875, -0.0271148681640625, -0.005924224853515625, 0.00988006591796875, 0.00807952880859375, -0.008056640625, 0.0037746429443359375, -0.0031108856201171875, -0.007144927978515625, -0.0207672119140625, -0.04278564453125, -0.0254364013671875, 0.01580810546875, 0.022003173828125, 0.00965118408203125, 0.00824737548828125, 0.00635528564453125, -0.005466461181640625, 0.01053619384765625, -0.0115203857421875, -0.00589752197265625, 0.03826904296875, 0.023956298828125, -0.014068603515625, -0.00342559814453125, 0.003681182861328125, -0.0078887939453125, -0.005397796630859375, 0.0275115966796875, 0.0030040740966796875, 0.0195770263671875, -0.0028171539306640625, -0.0035190582275390625, 0.01544189453125, 0.0121612548828125, -0.002773284912109375, 0.0165252685546875, -0.002216339111328125, 0.00542449951171875, 0.0181121826171875, -0.0168304443359375, 0.011138916015625, -0.0234527587890625, -0.00739288330078125, -0.0271759033203125, -0.0211639404296875, -0.0244140625, 0.0035877227783203125, -0.0025310516357421875, 0.0234527587890625, 0.0201568603515625, 0.0299224853515625, 0.0043792724609375, -0.0032405853271484375, -0.001468658447265625, -0.03363037109375, 0.01430511474609375, -0.00013136863708496094, 0.0006737709045410156, 0.0222625732421875, -0.0168304443359375, 0.007171630859375, -0.0086517333984375, -0.01013946533203125, 0.0207672119140625, -0.0207672119140625, 0.0060882568359375, -0.00823974609375, -0.011199951171875, -0.01235198974609375, -0.01064300537109375, -0.01277923583984375, -0.01268768310546875, -0.006008148193359375, -0.00655364990234375, -0.00493621826171875, 0.0173797607421875, 0.02178955078125, -0.0012712478637695312, -0.0012531280517578125, -0.0265655517578125, -0.00439453125, -0.00019478797912597656, 0.01088714599609375, 0.0202178955078125, 0.0131378173828125, 0.0045013427734375, -0.026519775390625, 0.0211029052734375, -0.017059326171875, -0.0157470703125, 0.001827239990234375, 0.00643157958984375, -0.0130462646484375, -0.004291534423828125, 0.00872802734375, -0.00649261474609375, 0.0185546875, 0.01396942138671875, -0.0185699462890625, 0.0025177001953125, -0.0099639892578125, -0.043121337890625, 0.041046142578125, -0.01268768310546875, 0.017547607421875, -0.023345947265625, -0.015777587890625, -0.0057220458984375, 0.00534820556640625, 0.015777587890625, 0.01181793212890625, -0.005542755126953125, -0.004878997802734375, -0.0275115966796875, 0.00567626953125, 0.025299072265625, -0.01099395751953125, -0.00019693374633789062, 0.005435943603515625, -0.007244110107421875, -0.01256561279296875, 0.0068359375, 0.0127410888671875, -0.00665283203125, 0.01334381103515625, 0.00496673583984375, 0.0254364013671875, -0.0111236572265625, 0.032196044921875, 0.0005445480346679688, -0.003665924072265625, -0.02386474609375, -0.0038852691650390625, 0.00778961181640625, -0.00417327880859375, 0.004291534423828125, 0.026397705078125, 0.01485443115234375, 0.0256805419921875, 0.0083770751953125, 0.0212249755859375, 0.018157958984375, 0.0006890296936035156, -0.002193450927734375, 0.0188140869140625, -0.01325225830078125, 0.0182952880859375, -0.00490570068359375, -0.033660888671875, -0.007404327392578125, 0.00853729248046875, 0.00635528564453125, -0.00438690185546875, 0.021087646484375, -0.019378662109375, -0.0030231475830078125, 0.0040740966796875, 0.00368499755859375, -0.00540924072265625, -0.0004744529724121094, 0.005985260009765625, 0.004291534423828125, 0.003314971923828125, 0.0208282470703125, 0.0222320556640625, 0.01401519775390625, 0.0095977783203125, 0.014892578125, -0.0223541259765625, 0.0108184814453125, -0.00304412841796875, -0.0059967041015625, -0.026092529296875, 0.024566650390625, -0.005428314208984375, 0.0080413818359375, -0.02508544921875, -0.0008282661437988281, 0.005374908447265625, 0.0082550048828125, 0.005741119384765625, -0.0021877288818359375, 0.01441192626953125, 0.01306915283203125, -0.017242431640625, 0.0245361328125, -0.0235595703125, -0.010101318359375, 0.0031719207763671875, -0.0188751220703125, -0.0033092498779296875, 0.01064300537109375, 0.00921630859375, -0.00015735626220703125, -0.00457763671875, -0.01451873779296875, 0.01030731201171875, -0.005260467529296875, 0.029083251953125, 0.00563812255859375, 0.0258941650390625, 0.001438140869140625, 0.0088958740234375, -0.0186004638671875, -0.0012483596801757812, -0.00457000732421875, 0.007396697998046875, 0.0210723876953125, -0.010955810546875, 9.5367431640625e-07, -0.0029392242431640625, 0.038604736328125, -0.02911376953125, -0.012939453125, -0.004100799560546875, -0.0190887451171875, -0.00379180908203125, -0.00963592529296875, -0.00360107421875, -0.0036296844482421875, 0.0127410888671875, -0.0130462646484375, -0.017303466796875, -0.0287017822265625, -0.0085601806640625, -0.0200958251953125, 0.01220703125, -0.00597381591796875, -0.0149993896484375, 0.0014362335205078125, -0.0141754150390625, 0.0202178955078125, -0.027740478515625, 0.0174560546875, -0.01535797119140625, 0.0080413818359375, 0.00991058349609375, 0.023101806640625, 0.03204345703125, -0.004669189453125, 0.006710052490234375, 0.006671905517578125, 0.0253753662109375, -0.017181396484375, -0.0241851806640625, -0.0148468017578125, 0.01116180419921875, 0.005512237548828125, 0.0014543533325195312, -0.0006232261657714844, -0.0109710693359375, 0.012054443359375, -0.00441741943359375, -0.0204010009765625, 0.01158905029296875, -0.008392333984375, -0.01142120361328125, -0.007343292236328125, 0.0012340545654296875, -0.00020515918731689453, 0.0003581047058105469, 0.0155029296875, 0.0036182403564453125, 0.0026531219482421875, 0.004520416259765625, 0.0036220550537109375, 0.0133056640625, -0.0008263587951660156, 0.0025959014892578125, 0.00228118896484375, -0.007213592529296875, -0.031494140625, 0.0006937980651855469, 0.0015783309936523438, 0.015289306640625, -0.0003643035888671875, 0.00817108154296875, -0.01763916015625, 0.003864288330078125, 0.015625, 0.00933074951171875, 0.0278472900390625, -0.0160980224609375, -0.0032520294189453125, -0.0133056640625, -0.01549530029296875, 0.0062408447265625, 0.01432037353515625, 0.00020778179168701172, 0.053955078125, -0.0340576171875, 0.004947662353515625, -0.004589080810546875, -0.003467559814453125, 0.00621795654296875, -0.023345947265625, 0.004886627197265625, -0.0017309188842773438, 0.018035888671875, 0.005786895751953125, 0.0164642333984375, 0.01470947265625, 0.0117340087890625, 0.0140533447265625, 0.0006685256958007812, 0.019927978515625, 0.004058837890625, -0.0135955810546875, -0.01556396484375, -0.006092071533203125, -0.01226806640625, -0.007476806640625, -0.01361846923828125, -0.0057220458984375, -0.0092010498046875, -0.00420379638671875, 0.005260467529296875, 0.006504058837890625, -0.00911712646484375, 0.012603759765625, 0.0008349418640136719, 0.00379180908203125, 0.00209808349609375, 0.00655364990234375, -0.022003173828125, -0.005443572998046875, 0.019256591796875, 0.003559112548828125, 0.029998779296875, -0.004947662353515625, -0.02520751953125, 0.01059722900390625, -0.00533294677734375, 0.01560211181640625, -0.0035762786865234375, 0.01085662841796875, -0.0227203369140625, 0.0029621124267578125, 0.00112152099609375, 0.028228759765625, 0.0136566162109375, 0.004604339599609375, -0.007259368896484375, -0.00626373291015625, 0.0283966064453125, -0.0102996826171875, 0.0019168853759765625, 0.01235198974609375, -0.006793975830078125, 0.0201416015625, -0.002483367919921875, 0.0147857666015625, 0.00980377197265625, -0.0099334716796875, 0.0004515647888183594, 0.006313323974609375, 0.002544403076171875, 0.0127716064453125, 0.0021419525146484375, -0.01541900634765625, 0.014434814453125, -0.011383056640625, -0.01418304443359375, -0.01178741455078125, 0.009674072265625, -0.0245361328125, 0.005023956298828125, 0.0271759033203125, -0.00823974609375, -0.005725860595703125, 0.0068206787109375, -0.0131072998046875, 0.0019989013671875, 0.018463134765625, -0.0261077880859375, -0.004222869873046875, 0.007511138916015625, -0.0121307373046875, -0.032318115234375, 0.0008406639099121094, 0.022186279296875, -0.0207366943359375, -0.01076507568359375, -0.044097900390625, -0.022796630859375, 0.0078582763671875, -0.01549530029296875, 0.00815582275390625, 0.0236358642578125, 0.00949859619140625, 0.001979827880859375, 0.01284027099609375, -0.01459503173828125, -0.0009636878967285156, 0.0155029296875, 0.019561767578125, -0.0162811279296875, 0.008880615234375, 0.0135955810546875, -0.0235137939453125, 0.0054473876953125, -0.004833221435546875, -0.01418304443359375, -0.024566650390625, 0.00933074951171875, -0.005619049072265625, -0.00656890869140625, 0.0190582275390625, -0.0086212158203125, -0.037567138671875, 0.0137786865234375, 0.042572021484375, 0.007541656494140625, -0.02197265625, 7.063150405883789e-05, -0.006443023681640625, 0.0206146240234375, 0.01361083984375, 0.0218658447265625, 8.916854858398438e-05, -0.01212310791015625, -0.016876220703125, -0.01300048828125, -0.00927734375, 0.0162200927734375, 0.01715087890625, -0.01087188720703125, 0.0011386871337890625, 0.01125335693359375, 0.0007309913635253906, 0.0236968994140625, -0.00926971435546875, -0.0114593505859375, -0.0006260871887207031, 0.006694793701171875, -0.00548553466796875, 0.006977081298828125, -0.019378662109375, -0.0283050537109375, 0.027984619140625, -0.033172607421875, 0.005832672119140625, -0.0205230712890625, 0.0032939910888671875, 0.00710296630859375, 0.0143890380859375, 0.006282806396484375, 0.0022735595703125, 0.016571044921875, 0.00775909423828125, 0.025726318359375, -0.001911163330078125, 0.01085662841796875, 0.033172607421875, -0.00262451171875, 0.006683349609375, 0.027008056640625, -0.0194091796875, -0.0019235610961914062, -0.00954437255859375, 0.0187225341796875, -0.0127105712890625, -0.01474761962890625, 0.0026531219482421875, -0.01238250732421875, -0.0285186767578125, -0.037933349609375, 0.015106201171875, 0.0214080810546875, 0.0033550262451171875, 0.020416259765625, -0.00597381591796875, 0.00881195068359375, -0.0229949951171875, 0.0228271484375, 0.0007104873657226562, -0.00635528564453125, -0.017242431640625, 0.007411956787109375, -0.00201416015625, -0.016387939453125, -0.0202789306640625, 0.0264434814453125, 0.01465606689453125, -0.0117034912109375, 0.025726318359375, -0.0230865478515625, 0.0061187744140625, 0.0040740966796875, -0.009429931640625, 0.0167694091796875, -0.0142059326171875, 0.0289154052734375, -0.0221405029296875, -0.0014200210571289062, 0.002773284912109375, 0.01432037353515625, 0.0279083251953125, -0.006412506103515625, -0.002109527587890625, 0.0162811279296875, -0.0110626220703125, 0.015167236328125, 0.00010406970977783203, 0.0162353515625, -0.0018873214721679688, -0.001880645751953125, -0.0029315948486328125, 0.03240966796875, 0.016937255859375, -0.0187530517578125, 0.009429931640625, 0.0007157325744628906, -5.5789947509765625e-05, -0.01345062255859375, 0.0156707763671875, -0.0229034423828125, -0.00963592529296875, 0.007568359375, -0.006175994873046875, -0.007541656494140625, -0.03887939453125, -0.0265960693359375, -0.00804901123046875, 0.01052093505859375, 0.017669677734375, 0.008026123046875, 0.013641357421875, 0.00507354736328125, -0.006626129150390625, -0.023468017578125, -0.007518768310546875, 0.0125885009765625, 0.01398468017578125, -0.0036220550537109375, 0.01403045654296875, -0.01062774658203125, -0.003650665283203125, 0.003009796142578125, -0.003360748291015625, -0.0242919921875, 0.0007138252258300781, -0.0287322998046875, -0.0223541259765625, 0.00189208984375, 0.0228424072265625, -0.0007290840148925781, 0.023345947265625, -0.002613067626953125, 0.0030059814453125, 0.0004553794860839844, 0.00635528564453125, 0.00243377685546875, 0.0012102127075195312, -0.0019245147705078125, 0.0117645263671875, -0.00646209716796875, 0.00014197826385498047, -0.0232391357421875, 0.01229095458984375, 0.002490997314453125, -0.0022525787353515625, 0.00548553466796875, -0.002483367919921875, -0.0025615692138671875, -0.01396942138671875, -0.01328277587890625, 0.0039520263671875, -0.005741119384765625, 0.01073455810546875, -0.02288818359375, -0.004497528076171875, -0.00621795654296875, -0.016326904296875, -0.0023021697998046875, -0.023529052734375, -0.01235198974609375, 0.0200653076171875, -0.00551605224609375, 0.0161590576171875, 0.001430511474609375, 0.0215301513671875, -0.0361328125, 0.00444793701171875, -0.003509521484375, -0.018798828125, -0.009124755859375, -0.00942230224609375, 0.005809783935546875, 0.02313232421875, 0.01441192626953125, -0.010467529296875, 0.025177001953125, -0.01367950439453125, -0.0140533447265625, -0.005908966064453125, -0.025604248046875, -0.0033931732177734375, 0.000965118408203125, -0.01398468017578125, -0.0085906982421875, 0.00940704345703125, 0.01015472412109375, -0.005428314208984375, -0.02398681640625, -0.0211639404296875, 0.00847625732421875, 0.00769805908203125, 0.0005488395690917969, 0.00643157958984375, -0.013824462890625, -0.0212860107421875, 0.01300811767578125, -0.0275726318359375, 0.01256561279296875, 0.01218414306640625, 0.0039005279541015625, 0.007099151611328125, 0.0009527206420898438, 0.018890380859375, -0.002410888671875, -0.0037326812744140625, -0.0084075927734375, 0.00476837158203125, -0.00942230224609375, 0.01424407958984375, 0.007694244384765625, 0.0038433074951171875, 0.006870269775390625, -0.00908660888671875, -0.010498046875, -0.002239227294921875, -0.0120391845703125, 0.0029754638671875, 0.00838470458984375, -0.0005102157592773438, -0.02777099609375, -0.0177001953125, 0.0008287429809570312, 0.020355224609375, 0.0283966064453125, -0.02447509765625, -0.04547119140625, -0.007381439208984375, -0.023895263671875, 0.010498046875, 0.0025196075439453125, 0.00858306884765625, 0.007381439208984375, 0.02392578125, 0.007152557373046875, -0.0008902549743652344, -0.01403045654296875, -0.01346588134765625, 0.03961181640625, -0.0010442733764648438, 0.0264434814453125, 0.005176544189453125, 0.00991058349609375, -0.0036716461181640625, -0.005786895751953125, -0.025543212890625, -0.00998687744140625, -0.0095367431640625, -0.0200042724609375, 0.0178375244140625, 0.00933074951171875, 0.0184173583984375, -0.01132965087890625, 0.03240966796875, 0.00262451171875, -0.00677490234375, -0.007404327392578125, 0.006893157958984375, -0.0211029052734375, -0.0186920166015625, 0.0291900634765625, 0.005893707275390625, 0.00390625, -0.01355743408203125, 0.014495849609375, 0.005275726318359375, -0.006313323974609375, -0.000751495361328125, -0.03460693359375, -0.019622802734375, -0.0041656494140625, 0.0214996337890625, -0.00998687744140625, 0.0032367706298828125, 0.01544189453125, 0.00594329833984375, 0.008880615234375, 0.03839111328125, -0.0294036865234375, -0.01390838623046875, 0.01641845703125, 0.00635528564453125, -0.006103515625, 0.004669189453125, -0.018463134765625, -0.0290374755859375, -0.00396728515625, 0.0112457275390625, 0.0117950439453125, -0.015869140625, 0.00981903076171875, 0.01001739501953125, -0.0189666748046875, -0.0212249755859375, -0.0035190582275390625, -0.022735595703125, -0.0247039794921875, -0.04290771484375, -0.00666046142578125, -0.0012865066528320312, -9.930133819580078e-05, -0.00011307001113891602, 0.01129913330078125, -0.014739990234375, -0.0075836181640625, 0.0194244384765625, 0.0216064453125, -0.015838623046875, -0.0180816650390625, -0.004024505615234375, -0.0157470703125, -0.01629638671875, 0.0014858245849609375, 0.003749847412109375, 0.00502777099609375, 0.0016155242919921875, -0.0237579345703125, -0.006992340087890625, 0.0169677734375, 0.01363372802734375, -0.040863037109375, -0.01678466796875, -0.0187835693359375, 0.0030803680419921875, 0.02288818359375, 0.00957489013671875, 0.005084991455078125, 0.0281982421875, 0.00811004638671875, -0.00518035888671875, -0.007213592529296875, 0.00820159912109375, -0.012115478515625, -0.009368896484375, -0.019195556640625, -0.00604248046875, -0.01629638671875, -0.01389312744140625, -0.01401519775390625, 0.0198211669921875, 0.0211029052734375, 0.00762176513671875, -0.0020885467529296875, 0.0223846435546875, 0.015899658203125, -0.01117706298828125, -0.0026874542236328125, 0.003162384033203125, -0.01334381103515625, -0.0022525787353515625, 0.0095672607421875, 0.00406646728515625, 0.00665283203125, -0.0116424560546875, 0.0312042236328125, 0.022308349609375, 0.01441192626953125, 0.0020961761474609375, 0.041046142578125, -0.05096435546875, 0.0026798248291015625, -0.0208282470703125, 0.01091766357421875, 0.0247039794921875, 0.0102081298828125, -0.0094451904296875, -0.00907135009765625, 0.03875732421875, 0.015625, 0.0148773193359375, -0.022369384765625, 0.01541900634765625, -0.0016565322875976562, 0.00933074951171875, -0.0030231475830078125, 0.003231048583984375, -0.005031585693359375, -0.0236968994140625, -0.0031108856201171875, 0.019195556640625, 0.02020263671875, -0.034576416015625, 0.020172119140625, 0.0081329345703125, 0.007068634033203125, 0.0142822265625, 0.00665283203125, -0.0058135986328125, 0.019073486328125, 0.015869140625, 0.0102996826171875, 0.0182342529296875, -0.011322021484375, -0.0296478271484375, -0.01611328125, 0.0203704833984375, 0.006557464599609375, -0.0163421630859375, 0.00848388671875, 0.0025615692138671875, -0.01265716552734375, -0.00909423828125, -0.0009412765502929688, -0.0091400146484375, 0.0203399658203125, -0.004863739013671875, 0.02276611328125, 0.0213775634765625, -0.03155517578125, -0.0133819580078125, -0.00966644287109375, -0.00909423828125, -0.00992584228515625, -0.0162811279296875, 0.0039005279541015625, 0.004344940185546875, -0.0166015625, -0.007781982421875, 0.005764007568359375, 0.0010213851928710938, -0.01016998291015625, 0.00528717041015625, 0.017486572265625, 0.0098114013671875, 0.007266998291015625, -0.00638580322265625, -0.01157379150390625, 0.008697509765625, 0.020599365234375, 0.019989013671875, 0.0308837890625, 0.024078369140625, -0.0244140625, 0.01015472412109375, 0.007415771484375, -0.00041937828063964844, -0.004749298095703125, 0.0186614990234375, 0.008270263671875, -0.01012420654296875, 0.00492095947265625, -0.0229034423828125, 0.00531768798828125, -0.0231170654296875, -0.0222930908203125, -0.014068603515625, -0.01215362548828125, 0.0085601806640625, 0.0159912109375, 0.00470733642578125, -0.0124053955078125, 0.01033782958984375, -0.0083465576171875, 0.019805908203125, -0.01459503173828125, -0.0008025169372558594, -0.0103607177734375, 0.01290130615234375, -0.00390625, 0.0197296142578125, -0.0166015625, -0.01209259033203125, 0.043182373046875, 0.01531219482421875, -0.01055145263671875, -0.02178955078125, -0.0016803741455078125, -0.0020732879638671875, -0.01311492919921875, 0.0002834796905517578, -0.01116943359375, -0.0092620849609375, 0.02947998046875, 0.0070343017578125, 0.0303192138671875, -0.008819580078125, 0.008880615234375, 0.0124664306640625, -0.015777587890625, 0.0229034423828125, 0.020263671875, -0.01580810546875, 0.0006318092346191406, 0.005985260009765625, 0.0072021484375, -0.0095977783203125, 0.0099334716796875, -0.0283966064453125, -0.026397705078125, 0.0078125, 0.0167236328125, -0.026214599609375, -0.007740020751953125, 0.0168304443359375, -0.01244354248046875, 0.027740478515625, -0.03887939453125, 0.0217742919921875, 0.01812744140625, -0.0110321044921875, 0.0184783935546875, -0.017730712890625, 0.007266998291015625, 0.00954437255859375, 0.020294189453125, -0.006702423095703125, 0.00804901123046875, -0.0025615692138671875, 0.006534576416015625, -0.00015795230865478516, -0.005985260009765625, -0.005207061767578125, -0.007205963134765625, -0.0097808837890625, 0.0298614501953125, -0.01226806640625, 0.00208282470703125, -0.004688262939453125, 0.01142120361328125, 0.006755828857421875, 0.0206451416015625, 0.0005674362182617188, 0.0216827392578125, -0.0016775131225585938, -0.01447296142578125, -0.0239715576171875, 0.0156402587890625, 0.0202178955078125, -0.00897979736328125, 0.0115814208984375, -0.01056671142578125, 0.006443023681640625, -0.0105438232421875, -0.0008115768432617188, 0.0012683868408203125, 0.002819061279296875, 0.01268768310546875, 0.01934814453125, -0.01035308837890625, 0.01496124267578125, -0.00933837890625, 0.0021038055419921875, 0.0019235610961914062, 0.0013990402221679688, -0.0113983154296875, -0.01065826416015625, 0.003215789794921875, 0.0179595947265625, 0.015777587890625, 0.002960205078125, 0.00749969482421875, 0.0218048095703125, 0.0072174072265625, 0.0159759521484375, -0.0258941650390625, 0.01105499267578125, -0.0281524658203125, -0.0157012939453125, -0.027099609375, -0.006160736083984375, -0.01434326171875, -0.0012178421020507812, -0.00902557373046875, -0.0084991455078125, 0.006946563720703125, -0.00864410400390625, -0.006946563720703125, -0.00392913818359375, 0.0102691650390625, -0.004940032958984375, -0.0010213851928710938, -0.01131439208984375, -0.017120361328125, -0.01507568359375, 0.0137176513671875, 0.004619598388671875, -0.006252288818359375, -0.00615692138671875, 0.025482177734375, 0.0040740966796875, 0.004604339599609375, 0.023468017578125, -0.0098724365234375, 0.0221099853515625, 0.01386260986328125, -0.0008101463317871094, 0.00527191162109375, -0.003360748291015625, -0.01232147216796875, 0.0025043487548828125, -0.017730712890625, 0.02911376953125, 0.0205230712890625, -0.02093505859375, -0.025848388671875, 0.0205841064453125, -0.032196044921875, 0.012237548828125, 0.01885986328125, 0.0006480216979980469, -0.002040863037109375, -0.0109100341796875, 0.008331298828125, 0.005268096923828125, -0.0168304443359375, -0.0100860595703125, -0.0023021697998046875, 0.03912353515625, 0.01593017578125, 0.025054931640625, 0.00150299072265625, 0.01934814453125, 0.0014362335205078125, 0.0168304443359375, -0.004734039306640625, -0.01323699951171875, 0.0033359527587890625, -0.0045166015625, 0.0092315673828125, 0.0007929801940917969, 0.02398681640625, -0.0094451904296875, -0.01541900634765625, 0.018310546875, -0.033782958984375, -0.00649261474609375, 0.0166015625, 0.00501251220703125, 0.017364501953125, 0.0205841064453125, -0.005229949951171875, -0.01122283935546875, 0.01493072509765625, 0.020843505859375, -0.0059356689453125, -0.006359100341796875, -0.0230255126953125, 0.031646728515625, 0.01422119140625, 0.01123046875, 0.0153350830078125, -0.00811004638671875, 0.0013704299926757812, -0.00983428955078125, 0.005218505859375, -0.0200347900390625, 0.006359100341796875, -0.0021114349365234375, -0.036956787109375, -0.01436614990234375, -0.0011930465698242188, 0.01392364501953125, -0.01345062255859375, -0.0009584426879882812, -0.017547607421875, 0.019378662109375, 0.020172119140625, 0.00939178466796875, 0.0286865234375, -0.01023101806640625, 0.0037689208984375, -0.0169525146484375, -0.01184844970703125, -0.0075531005859375, -0.0029773712158203125, -0.0187530517578125, -0.020355224609375, -0.0201568603515625, -0.0117340087890625, -0.0263519287109375, -0.01091766357421875, -0.0020198822021484375, -0.0186767578125, 0.01088714599609375, 0.028106689453125, -0.017364501953125, 0.023834228515625, -0.001720428466796875, -0.01087188720703125, 0.006343841552734375, 0.0086212158203125, 0.0092010498046875, -0.006755828857421875, 0.007694244384765625, -0.005462646484375, -0.0117340087890625, 0.0108489990234375, -0.01203155517578125, -0.006877899169921875, 0.026336669921875, -0.0026092529296875, 0.006694793701171875, -0.019500732421875, 0.00433349609375, -0.00279998779296875, -0.016693115234375, -0.00568389892578125, -0.00917816162109375, -0.0018825531005859375, 0.01099395751953125, 0.006671905517578125, 0.00521087646484375, -0.0042266845703125, -0.01372528076171875, -0.020355224609375, -0.019073486328125, 0.0086669921875, 0.006252288818359375, -0.00923919677734375, -0.007415771484375, -0.006420135498046875, 0.016571044921875, -0.00150299072265625, 0.00827789306640625, -0.004589080810546875, -0.0107574462890625, 0.0041656494140625, -0.0164642333984375, 0.01006317138671875, 0.0178375244140625, 0.0162200927734375, 0.006412506103515625, 3.93986701965332e-05, 0.0063018798828125, 0.01448822021484375, -0.0019683837890625, -0.004077911376953125, -0.0014019012451171875, 0.006923675537109375, -0.02789306640625, 0.01334381103515625, -0.0318603515625, 8.559226989746094e-05, 0.0016908645629882812, -0.00927734375, 0.0019989013671875, 0.0194549560546875, -0.00789642333984375, -0.005252838134765625, 0.00948333740234375, -0.0042724609375, 0.012542724609375, -0.00592803955078125, -0.0013103485107421875, 0.007320404052734375, -0.0095672607421875, -0.03558349609375, -0.00666046142578125, -0.006103515625, -0.019073486328125, 0.00536346435546875, -0.017120361328125, -0.007061004638671875, 0.028564453125, -0.0168914794921875, 0.007549285888671875, -0.0137176513671875, -0.0044403076171875, 0.00885009765625, -0.00799560546875, 0.014373779296875, -0.005336761474609375, 0.00516510009765625, 0.0128021240234375, 0.0186614990234375, 0.0271759033203125, -0.01392364501953125, -0.01369476318359375, 0.008758544921875, -0.0016107559204101562, -0.027740478515625, -0.00920867919921875, 0.01282501220703125, 0.0256805419921875, 0.0174407958984375, 0.021881103515625, 0.0114288330078125, 0.007328033447265625, 0.007373809814453125, -0.016998291015625, -0.006145477294921875, -0.00447845458984375, -0.0214691162109375, 0.00565338134765625, -0.002513885498046875, -0.002407073974609375, 0.03619384765625, 0.0245361328125, -0.0291595458984375, -0.01416015625, 0.005741119384765625, 0.00391387939453125, -0.015899658203125, 0.003879547119140625, 0.0007443428039550781, 0.0012645721435546875, 0.017791748046875, -0.00485992431640625, -0.01555633544921875, -0.00556182861328125, -0.0014734268188476562, -0.0260009765625, 0.0106658935546875, 0.007488250732421875, 0.0034923553466796875, 0.030487060546875, 0.01419830322265625, 0.002796173095703125, -0.0009465217590332031, -0.0083770751953125, 0.0265960693359375, 0.019256591796875, -0.00992584228515625, -0.0082244873046875, 0.017547607421875, 0.005924224853515625, -0.029022216796875, -0.003665924072265625, -0.006702423095703125, 0.005077362060546875, 0.0293731689453125, 0.043792724609375, 0.00673675537109375, 4.76837158203125e-07, -0.005504608154296875, 0.022491455078125, -0.018096923828125, 0.0118255615234375, 0.0008459091186523438, -0.0252532958984375, 0.0001291036605834961, -0.017181396484375, -0.000942230224609375, 0.0087127685546875, -0.003719329833984375, -0.0085906982421875, 0.005153656005859375, -0.0111541748046875, 0.0032825469970703125, -0.0017690658569335938, 0.01403045654296875, -0.005390167236328125, -0.01357269287109375, -0.01934814453125, 0.0016393661499023438, 0.0024623870849609375, -0.0029544830322265625, -0.0187835693359375, 0.0008654594421386719, 0.01074981689453125, -0.0117340087890625, -0.016326904296875, 0.0089569091796875, -0.00441741943359375, 0.0081787109375, -0.00440216064453125, 0.0019550323486328125, 0.01238250732421875, 0.031005859375, 0.0097503662109375, -0.0016527175903320312, 0.00893402099609375, 0.01235198974609375, 0.0069122314453125, -0.0012235641479492188, 0.0283203125, -0.0106353759765625, 0.01181793212890625, 0.0151824951171875, -0.0004608631134033203, 0.00782012939453125, 0.0200347900390625, 0.0004940032958984375, -0.0197296142578125, 0.022918701171875, 0.00423431396484375, -0.0036487579345703125, -0.01361846923828125, 0.01157379150390625, -0.004108428955078125, 0.0010633468627929688, 0.0200347900390625, 0.019744873046875, 0.00928497314453125, -0.0007677078247070312, 0.0135040283203125, -0.025299072265625, 0.004241943359375, -0.001758575439453125, 0.0166473388671875, -0.0019006729125976562, -0.0280303955078125, 0.004650115966796875, -0.00505828857421875, -0.006557464599609375, -0.0179901123046875, 0.002864837646484375, -0.02398681640625, 0.03857421875, -0.033905029296875, -0.00435638427734375, 0.010498046875, 0.0096893310546875, -0.01027679443359375, 0.00018513202667236328, -0.0001474618911743164, 0.0199737548828125, 0.004871368408203125, -0.004978179931640625, -0.005462646484375, -0.01690673828125, 0.007228851318359375, -0.0279083251953125, -0.01617431640625, -0.01715087890625, 0.0016031265258789062, -0.00042724609375, 0.0228424072265625, 0.0007867813110351562, 0.00278472900390625, -0.0008916854858398438, -0.014892578125, 0.01175689697265625, -0.022857666015625, 0.0004661083221435547, 0.004291534423828125, 0.0008692741394042969, -0.0156097412109375, 0.0030040740966796875, -0.0008769035339355469, 0.006328582763671875, 0.0157928466796875, 0.0111541748046875, 0.042266845703125, 0.019989013671875, -0.0079803466796875, 0.0265960693359375, 0.0138397216796875, 0.01302337646484375, 0.0013589859008789062, -0.00395965576171875, 0.005115509033203125, -0.00505828857421875, 0.0027217864990234375, 0.0203399658203125, 0.0200653076171875, -0.00305938720703125, 0.005054473876953125, -0.0184173583984375, -0.0035648345947265625, -0.005153656005859375, -0.0008077621459960938, -0.056732177734375, -0.0214691162109375, -0.0207672119140625, 0.0211029052734375, -0.021820068359375, -0.00554656982421875, 0.0019369125366210938, 0.0145111083984375, -0.00365447998046875, 0.0006432533264160156, -0.0016002655029296875, -0.016510009765625, 0.0030670166015625, -0.0287017822265625, -0.01149749755859375, -0.017791748046875, -0.00493621826171875, -0.005191802978515625, 0.0019893646240234375, 0.005352020263671875, 0.0159912109375, 0.0270538330078125, 0.0158233642578125, 0.003627777099609375, -0.03045654296875, -0.0254364013671875, -0.01480865478515625, -0.0131988525390625, -0.0113677978515625, 0.024078369140625, -0.01424407958984375, -0.0003254413604736328, 0.025604248046875, -0.0032711029052734375, 0.0023212432861328125, -0.007404327392578125, -0.0129852294921875, -0.011474609375, 0.003818511962890625, 0.007965087890625, 0.019989013671875, -0.020294189453125, 0.007694244384765625, -0.0036029815673828125, 0.002315521240234375, -0.00649261474609375, 0.0082855224609375, -0.01403045654296875, -0.01409912109375, 0.0006895065307617188, -0.0113677978515625, 0.0008993148803710938, 0.00024628639221191406, 0.01111602783203125, 0.00382232666015625, 0.003292083740234375, -0.0036869049072265625, -0.0182342529296875, -0.01076507568359375, 0.014892578125, 0.0040130615234375, 0.041656494140625, 0.01055145263671875, -0.005741119384765625, 0.024169921875, -0.0042724609375]\n"
     ]
    }
   ],
   "source": [
    "# from openai import OpenAI\n",
    "# load_dotenv()\n",
    "\n",
    "# client = OpenAI(\n",
    "#   api_key= os.getenv(\"NIM_APIKEY\"),\n",
    "#   base_url=\"https://integrate.api.nvidia.com/v1\"\n",
    "# )\n",
    "\n",
    "# response = client.embeddings.create(\n",
    "#     input=[\"What is the capital of France?\"],\n",
    "#     model=\"nvidia/nv-embedqa-mistral-7b-v2\",\n",
    "#     encoding_format=\"float\",\n",
    "#     extra_body={\"input_type\": \"query\", \"truncate\": \"NONE\"}\n",
    "# )\n",
    "\n",
    "# print(response.data[0].embedding)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 88,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Valid NVIDIA_API_KEY already in environment. Delete to reset\n"
     ]
    }
   ],
   "source": [
    "import getpass\n",
    "import os\n",
    "\n",
    "# del os.environ['NVIDIA_API_KEY']  ## delete key and reset\n",
    "if os.environ.get(\"NVIDIA_API_KEY\", \"\").startswith(\"nvapi-\"):\n",
    "    print(\"Valid NVIDIA_API_KEY already in environment. Delete to reset\")\n",
    "else:\n",
    "    nvapi_key = getpass.getpass(\"NVAPI Key (starts with nvapi-): \")\n",
    "    assert nvapi_key.startswith(\n",
    "        \"nvapi-\"\n",
    "    ), f\"{nvapi_key[:5]}... is not a valid key\"\n",
    "    os.environ[\"NVIDIA_API_KEY\"] = nvapi_key\n",
    "    \n",
    "embedder = NVIDIAEmbedding(model=\"NV-Embed-QA\", truncate=\"END\")\n",
    "\n",
    "nim_llm = NVIDIA(model=\"mistralai/mistral-7b-instruct-v0.2\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'embedder' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[14], line 8\u001b[0m\n\u001b[0;32m      1\u001b[0m vector_store \u001b[38;5;241m=\u001b[39m MilvusVectorStore(\n\u001b[0;32m      2\u001b[0m             dim\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m1024\u001b[39m,\n\u001b[0;32m      3\u001b[0m             collection_name\u001b[38;5;241m=\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mmilvus_test\u001b[39m\u001b[38;5;124m\"\u001b[39m,\n\u001b[0;32m      4\u001b[0m             uri\u001b[38;5;241m=\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mhttp://localhost:19530/\u001b[39m\u001b[38;5;124m\"\u001b[39m,\n\u001b[0;32m      5\u001b[0m             overwrite\u001b[38;5;241m=\u001b[39m\u001b[38;5;28;01mTrue\u001b[39;00m\n\u001b[0;32m      6\u001b[0m         )\n\u001b[1;32m----> 8\u001b[0m chunks \u001b[38;5;241m=\u001b[39m \u001b[43mchunk_document\u001b[49m\u001b[43m(\u001b[49m\u001b[43mdocuments\u001b[49m\u001b[43m)\u001b[49m\n\u001b[0;32m      9\u001b[0m storage_context \u001b[38;5;241m=\u001b[39m StorageContext\u001b[38;5;241m.\u001b[39mfrom_defaults(vector_store\u001b[38;5;241m=\u001b[39mvector_store)\n\u001b[0;32m     10\u001b[0m vector_store_index \u001b[38;5;241m=\u001b[39m VectorStoreIndex(nodes\u001b[38;5;241m=\u001b[39mchunks,vector_store\u001b[38;5;241m=\u001b[39mvector_store, embed_model\u001b[38;5;241m=\u001b[39membed_model, storage_context\u001b[38;5;241m=\u001b[39mstorage_context)\n",
      "Cell \u001b[1;32mIn[12], line 5\u001b[0m, in \u001b[0;36mchunk_document\u001b[1;34m(documents)\u001b[0m\n\u001b[0;32m      1\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21mchunk_document\u001b[39m(documents):\n\u001b[0;32m      3\u001b[0m     base_splitter \u001b[38;5;241m=\u001b[39m SentenceSplitter(chunk_size\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m512\u001b[39m)\n\u001b[0;32m      4\u001b[0m     splitter \u001b[38;5;241m=\u001b[39m SemanticSplitterNodeParser(\n\u001b[1;32m----> 5\u001b[0m         buffer_size\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m1\u001b[39m, breakpoint_percentile_threshold\u001b[38;5;241m=\u001b[39m\u001b[38;5;241m95\u001b[39m, embed_model\u001b[38;5;241m=\u001b[39m\u001b[43membedder\u001b[49m, base_splitter\u001b[38;5;241m=\u001b[39mbase_splitter\n\u001b[0;32m      6\u001b[0m     )\n\u001b[0;32m      7\u001b[0m     chunks \u001b[38;5;241m=\u001b[39m splitter\u001b[38;5;241m.\u001b[39mget_nodes_from_documents(documents)\n\u001b[0;32m      9\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m chunks\n",
      "\u001b[1;31mNameError\u001b[0m: name 'embedder' is not defined"
     ]
    }
   ],
   "source": [
    "vector_store = MilvusVectorStore(\n",
    "            dim=1024,\n",
    "            collection_name=\"milvus_test\",\n",
    "            uri=\"http://localhost:19530/\",\n",
    "            overwrite=True\n",
    "        )\n",
    "\n",
    "chunks = chunk_document(documents)\n",
    "storage_context = StorageContext.from_defaults(vector_store=vector_store)\n",
    "vector_store_index = VectorStoreIndex(nodes=chunks,vector_store=vector_store, embed_model=embed_model, storage_context=storage_context)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "embed_model = AzureOpenAIEmbedding(\n",
    "    engine=\"text-embedding-ada-002\",\n",
    "    model=\"text-embedding-ada-002\",\n",
    "    api_version=\"2024-07-01-preview\",\n",
    "    azure_endpoint=os.getenv('AZURE_3.5_ENDPOINT'),\n",
    "    api_key=os.getenv('AZURE_3.5_API_KEY')\n",
    ")\n",
    "\n",
    "llm = AzureOpenAI(\n",
    "    engine=\"gpt-35-turbo\",\n",
    "    api_version=\"2024-07-01-preview\",\n",
    "    azure_endpoint=os.getenv('AZURE_3.5_ENDPOINT'),\n",
    "    api_key=os.getenv('AZURE_3.5_API_KEY'),\n",
    "    model=\"gpt-35-turbo\",\n",
    "    temperature=0,\n",
    "    top_p=0\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "reader = SimpleDirectoryReader(input_files=[\"./../data/test.pdf\"])\n",
    "documents = reader.load_data()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(id_='9969a1ba-97bd-4c7e-9ea3-ca91a8e9d077', embedding=None, metadata={'page_label': '385', 'file_name': 'test.pdf', 'file_path': '..\\\\data\\\\test.pdf', 'file_type': 'application/pdf', 'file_size': 527692, 'creation_date': '2024-10-12', 'last_modified_date': '2024-10-12'}, excluded_embed_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], excluded_llm_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], relationships={}, text=\"Annals of Oncology 10: 385-390, 1999.\\n© 1999 Kluwer Academic Publishers. Printed  in the Netherlands.\\nSpecial article\\nEssential drugs for cancer therapy:  A World Health Organization\\nconsultation\\nK. Sikora,1 S. Advani,2 V. Koroltchouk,1 I. Magrath,3 L. Levy,4 H. Pinedo,5 G. Schwartsmann,6\\nM.Tattersall7 & S.Yan8\\n1 WHO Cancer Programme, International Agency for Research on Cancer, Lyon, France; 2Department of Medical Oncology, Tata Memorial\\nHospital, India; 3National Cancer Institute, Bethesda, MD, USA, 4 Department of Medicine, University of Zimbabwe, Harare, Zimbabwe,\\niVrije Universiteit, Department of Medical Oncology. Amsterdam, The Netherlands; 6 Hospital de Clinicas de Porto Alegre, Universidade Federal\\ndo Rio Grande do Sul, Porto Alegre, Brazil; ''Department of Cancer Medicine, University of Sydney, Australia; 8 Department of Medical Oncology,\\nCancer Hospital, Chinese Academy of Medical Sciences, Beijing, China\\nSummary\\nThe WHO has previously produced recommendations on the\\nessential drugs required for cancer therapy. Over the last five\\nyears several new anti cancer drugs have been aggressivelymarketed. Most of these are costly and produce only limitedbenefits.\\n We have divided currently available anti-cancer drugs\\ninto three priority groups. Curable cancers and those cancerswhere the cost-benefit ratio clearly favours drug treatment canbe managed appropriately with regimens based on only\\n 17 drugs.\\nAll of these are available, at relatively low cost, as genericpreparations. The wide availability of these drugs should be\\nthe first priority. The second group of drugs may have some\\nadvantages in certain clinical situations. Based on currentevidence, drugs in the third group are judged as currently notessential for the effective delivery of cancer care. Adequate\\nsupportive care programmes with the widespread availabilityof effective drugs for pain control are of considerably greaterimportance. The adoption of these priorities will help tooptimise the effectiveness and efficiency of chemotherapy and\\nensure equitable access to essential drugs especially in low\\nresource environments. Clearly this paper represents the views\\nof its contributors. The WHO welcomes feedback from alloncologists so that the advice it gives to governments in priori-tising the procurement of anti cancer drugs can be as compre-hensive as possible.\\nKey words: chemotherapy, drugs, generics, prioritization\\nIntroduction\\nCancer is an important and increasing cause of morbidity\\nand mortality worldwide. Currently, 10 million new\\ncancer patients are detected each year and six million\\npeople die of the disease. We estimate that these figureswill be 20 million and\\n 10 million respectively by the year\\n2020.  Many cancer patients, if diagnosed at an early\\nstage and given appropriate treatment, will subsequentlylive a normal life-span. Useful palliation can be achieved\\nfor all patients. Effective cancer care requires the linkage\\nof early diagnosis to the appropriate use of surgery,radiotherapy, cytotoxic and endocrine therapies as well\\nas supportive care including analgesics, antibiotics, and\\nblood products. Such treatments may be complex in-volving different specialists and not all may be availablein every hospital. They are also costly making theoptimal organisation of cancer services important in all\\neconomic environments.\\nThe provision of cancer treatment services, including\\nchemotherapy, is an essential component of a nationalcancer programme (NCP). These programmes offer a\\nrational mechanism for implementing existing knowl-\\nedge on primary prevention, early diagnosis, screening,optimal treatment services and symptom control. The\\nWHO has produced a cancer priority ladder which can beadapted to the resources available and the epidemiology\\nof cancer in a specific country. The formation of\\n an NCP\\nis an important health priority [1,  2]. Even with limited\\nresources, a systematic, planned approach can yield sub-\\nstantial medical and social benefits. Some common\\ntumours can be treated with a good chance of cure, so\\nthat treatment services should be readily accessible.Some relatively rare but curable cancers require highly\\nspecialised facilities for optimal care such as the acute\\nleukaemias and paediatric tumours\\n [3]. Unless adequate\\nresources and facilities are available, it is inappropriate\\nto acquire the drugs which are required to treat these\\ncancers. For other tumours such as hepatoma and lungcancer the development of effective prevention pro-grammes through hepatitis\\n B immunisation and tobacco\\ncontrol will clearly be of greater priority than therapyfor the immediate future. Downstaging strategies inbreast and cervical cancer by early detection programmes\\nand effective referral guidelines will provide a larger\\nhealth gain in certain situations. The cost effectivenessof chemotherapy will clearly vary across the globally\\ndiverse epidemiological and economic spectrum.\", mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='cb12e04b-eccd-44f5-9f6a-a356ec9be639', embedding=None, metadata={'page_label': '386', 'file_name': 'test.pdf', 'file_path': '..\\\\data\\\\test.pdf', 'file_type': 'application/pdf', 'file_size': 527692, 'creation_date': '2024-10-12', 'last_modified_date': '2024-10-12'}, excluded_embed_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], excluded_llm_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], relationships={}, text=\"386\\nCancer chemotherapy, like surgery and radiation ther-\\napy is an essential component of modern cancer care.\\nMedical staff must have appropriate training, knowl-\\nedge and access to the requisite facilities to deliver and\\nmonitor chemotherapy. A properly directed and inte-grated team approach with experts in at least pathology,\\nsurgery, radiation therapy and medicine is essential foroptimal outcomes at an acceptable cost.\\nTo assist the WHO Expert Committee on the Use of\\nEssential Drugs in their selection of drugs for cancer\\nchemotherapy, the WHO invited medical oncologists\\nfrom five continents to review the essential drugs list for\\ncancer which had been formulated initially in 1985 [4]\\nand revised in 1994 [5].\\nGeneral principles\\nPrior to the initiation of any cancer treatment, the goal\\nof therapy must be realistically defined. Individual prog-\\nnostic factors should be determined such as the stage of\\ndisease [6], the sites of metastases, the histology of the\\ntumour, the general medical status of the patient, the\\npatient's willingness to accept the anticipated toxicity,\\nand the availability of necessary facilities and personnel\\nto treat complications. Although a particular tumour\\ntype may be curable in some instances, clearly not allpatients with that tumour type will be cured. The risk -benefit concept needs to be discussed with the patient inadvance. Increasingly patients are being given far moreinformation about cancer and the options available tothem. Furthermore the Internet provides a readily ac-\\ncessible international resource on cancer including\\ndrugs and is used by many patients and their families\\n[7]. Commonly used sites include Oncoweb, Oncolink,\\nCancernet, PDQ. These are well contructed sites with\\nreliable information. Unfortunately, the quality of many\\nother sites is highly variable. Cancer chemotherapy\\nrequires access to laboratory facilities to monitor blood\\ncounts as well as liver and renal function. The assessment\\nof tumour response in patients with measurable tumours\\nmust be made at appropriate intervals to determine if\\nthe treatment is effective and if the patient should con-tinue therapy.\\nSome principles of chemotherapy are well established.\\nThe initial therapies employed are often the most impor-\\ntant in determining their outcome\\n [8]. Therapy should not\\nbe unnecessarily delayed, nor should a suboptimal treat-ment programme be given. Managers and patients must\\nunderstand that simply reducing the standard dosage\\nadministered or the number of courses given to save\\ncosts is unacceptable. For tumours sensitive to chemo-\\ntherapy a combination of drugs, each employed at an\\noptimal dose, is more likely to induce tumour responseand result in meaningful benefit. The treatment of pa-\\ntients with a minimal tumour burden is usually more\\neffective. The results of numerous clinical trials in recent\\nyears clearly demonstrate that certain patient groupswith operable breast [9] and colorectal cancer [10] sur-vive longer when given systemic therapy after tumour\\nresection. The implications of these new data are that a\\nlarge number of additional patients may benefit from\\nchemotherapy. Recently several high cost drugs have\\nbeen marketed for common cancers. Although capable\\nof a significant response rate in patients with metastatic\\ndisease, such responses are often of short duration and\\nmay only prolong median survival by a few weeks to\\nmonths. To what extent some of these new drugs should\\nreplace older and cheaper agents has not yet been deter-\\nmined in well designed trials with relevant endpoints\\nincluding cost benefit assessment. Prioritisation mustbe based on the relative efficacy and cost effectiveness of\\nspecific drugs\\n [11].  Inevitably this will have a subjective\\nelement and will vary with the overall allocation tocancer treatment in a country.\\nTumour categories\\nThere are more than 200 types of cancer and these\\nrespond variably to chemotherapy. Tumours can be use-\\nfully split into five categories with regard to the relativeusefulness of chemotherapy. This provides a basis for\\nexamining the overall health gain of defined interven-\\ntions.\\nCategory  1. Tumours for which there is evidence that\\nthe use of a single or a combination of drugs used aloneor with other therapeutic modalities will result in cure as\\ndefined by a normal life-span in some and a prolonga-\\ntion of survival in most patients.\\nCategory 2. Tumours where the average survival is\\nprolonged when chemotherapy is used as an adjuvantto local surgery or radiotherapy in early stages of dis-\\nease.\\nCategory  3. Tumours for which there is evidence that\\nthe use of  one drug or a combination of drugs will cause\\ntumour shrinkage in more than 20% of selected patientswith metastatic disease with almost certain improve-ment in the quality of life. Prolongation of survivaloccurs in most of the responding patients but may be of\\nshort duration.\\nCategory 4. Tumours where local control may be im-\\nproved by the use of chemotherapy before, during orafter surgery and radiotherapy.\\nCategory  5. Tumours for which there are currently no\\neffective drugs. Objective responses occur in less than\\n20% of patients and there is no evidence of survival\\nbenefit in randomised controlled trials when comparedto best supportive care.\\nTable 1 divides the commonly occurring cancers into\\neach of these\\n five categories.\", mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='3fda9732-36bf-475f-bfb3-7d5aad98a931', embedding=None, metadata={'page_label': '387', 'file_name': 'test.pdf', 'file_path': '..\\\\data\\\\test.pdf', 'file_type': 'application/pdf', 'file_size': 527692, 'creation_date': '2024-10-12', 'last_modified_date': '2024-10-12'}, excluded_embed_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], excluded_llm_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], relationships={}, text=\"387\\nTable 1. Cancers grouped according to the effectiveness of chemo-\\ntherapy and hormonal therapy.\\nCategory 1. potentially curable even with systemic disease\\nGerm-cell cancers\\nTrophoblastic cancers\\nAcute lymphoblastic leukaemiaAcute myeloid leukaemiaAcute promyelocytic leukaemia\\nHairy cell leukaemia\\nHodgkin's disease and non-Hodgkin's lymphoma\\nCategory 2. adjuvant chemotherapy of established benefit in local\\ndisease\\nColo-rectal cancer (Dukes C)\\nBreast cancer\\nOvarian cancer\\nOsteosarcoma\\nEwing's sarcomaNeuroblastoma\\nRetinoblastoma\\nSoft tissue sarcoma\\nWilms' tumour\\nCategory 3, palliative benefit only in metastatic disease\\nLung cancer\\nSmall-cell - relatively long durationNon-small-cell - relatively short duration\\nOvarian cancer\\nChronic lymphocytic and myelogeneous leukaemia\\nAnal cancer\\nBladder cancerEndometrial cancerProstate cancer\\nKaposi's sarcoma (non-HlV)\\nIndolent AIDS-related lymphoma and Kaposi's sarcoma\\nAdult soft tissue sarcoma\\nColorectal cancer\\nCervical cancer\\nHead and neck cancer\\nOesophageal cancer\\nStomach cancer\\nBreast Cancer\\nCategory 4, local control enhanced\\nOropharyngeal cancer\\nNasopharyngeal cancer\\nCategory 5, chemotherapy ineffective\\nAIDS-related CNS lymphoma\\nHepatobiliary cancersMelanomaPancreatic cancerRenal-cell cancer\\nThyroid cancer\\nCentral nervous system cancers\\nPrioritising anti-cancer drugs\\nWe have banded anti-cancer drugs into three priority\\nlevels.  The determination of the priority grouping of a\\ndrug is based on its utility in treating category 1, 2 and 3\\ntumours and the global incidence of the responding\\ntumours. Table 2 shows the effects of systemic therapy\\nin the treatment of  the ten most common cancers world-\\nwide. Unfortunately, good responses outside the adjuvant\\nsituation are limited for most of these tumours. We haveidentified 13 effective drugs which provide beneficialTable 2. Effects of systemic therapy on the ten most common cancers\\nworldwide.\\nCancer Category\\nLung\\nStomach\\nBreast\\nColorectal\\nCervix\\nHead and neck\\nLymphomaHepatobiliary\\nOesophagus\\nProstate\\nTable  3. Cancer drug priority list.\\nTop 10 cancers Category 1-2 Generic\\nPriority 1\\nBleomycin + + +\\nChlorambucil + + +\\nCisplatin + + +\\nCyclophosphamide + + +\\nDoxorubicin + + +\\nEtoposide + + +\\n5-Fluorouracil  + + +\\nMethotrexate + + +Prednisolone + + +\\nProcarbazine + +\\nTamoxifen + + +\\nVincristine + + +Vinblastine + + +Cytarabine + +\\nDactinomycin + +\\nDaunorubicin + +\\n6-Mercaptopurine  + +\\nTogether with two antiemetics - a dopamine receptor and a  5-HT 3\\nreceptor antagonist as well as dexamethasone\\nPriority 2\\nBusulphan + +\\nCarboplatin +\\nFlutamide +\\nFolinic acid + +\\nInterferon alpha +LHRH analogues +\\nMelphalan +\\nMegestrol acetate + +Mitomycin C +Mitoxantrone + +\\nPaclitaxel +\\nVinorelbine +\\nPriority 3\\nAminoglutethimide + +Anastrozole +\\nAltretamine\\nBCNU, CCNU +\\nDacarbazine +Docetaxel +\\nEpirubicin + +\\nGemcitabine +\\nIfosfamide\\nIrinotecan +\\nRaltitrexed +\\nTopotecan\", mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='07ce46a3-3027-4d96-9bbf-edd718844936', embedding=None, metadata={'page_label': '388', 'file_name': 'test.pdf', 'file_path': '..\\\\data\\\\test.pdf', 'file_type': 'application/pdf', 'file_size': 527692, 'creation_date': '2024-10-12', 'last_modified_date': '2024-10-12'}, excluded_embed_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], excluded_llm_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], relationships={}, text='388\\nTable  4. The WHO cancer priority ladder.\\nTobacco control.\\nInfection control.\\nCurable cancer programme.\\nEffective pain control.\\nEarly detection strategy.\\nSample cancer registry.\\nHealthy eating programme.\\nReferral guidelines.\\nClinical care guidelines.\\nNurse education.\\nNational cancer network.\\nClinical evaluation unit.\\nPlatform technology focus for region.\\nClinical research programme.\\nBasic research programme.\\nInternational aid programme.\\noutcomes against certain common tumours (Table 3)\\nwith a further four drugs necessary for the treatment ofleukaemia. Thus, 17 drugs can be considered in priority\\none and are thus essential. In preparing this list of drugs,\\nevidence of benefit was accepted only from scientifically\\nvalid clinical research. This has permitted the rationalselection of essential drugs from more than 100 commer-\\ncially available preparations. All 17 are widely available\\nas generic preparations of relatively low cost.\\nA second group of drugs is listed in priority 2. These\\nhave well documented benefits in certain clinical situa-\\ntions.  They are not truly essential as either drugs from\\nthe priority 1 list can be used as substitutes or their\\neffects are only palliative. Cheaper and simpler forms of\\npalliation with radiotherapy or analgesics may be more\\nappropriate in low resource environments. Few of these\\ndrugs are available as generic preparations. The taxanes\\nhave generated considerable public interest. A rando-mised controlled trial in the USA demonstrated a 13month survival advantage for women treated with pacli-taxel and cisplatin as first line chemotherapy for ovarian\\ncancer when compared to cyclophosphamide and cis-\\nplatin [11]. This has been confirmed by a Canadian-\\nEuropean study\\n [12].  Several studies are still in progress\\nto verify these results. The additional cost of the taxane\\nper quality adjusted life year (QUALY) has been calcu-lated at USS2000 per patient [13]. Paclitaxel wouldtherefore move into priority 1 group if its benefit is\\nclearly reproducible. The use of paclitaxel as second or\\nthird line therapy is not cost effective with a cost perQUALY of over US$30,000. The LHRH analogues are\\nuseful in palliating metastatic prostate cancer [14].\\nAlthough effective, they are costly and require frequent\\nclinic attendances. Prostate cancer is dramatically in-creasing in incidence globally due to ageing populations.\\nAn oral formulation could change the priority category.\\nMany of the drugs in the priority three group are\\nrecent, expensive and of\\n low effectiveness. About half  of\\npatients with metastatic breast cancer respond to doce-taxel. The side effects are significant and the median\\nresponse duration is only five to six months [15]. Altret-amine [16] and topotecan [17] are being marketed for\\nadvanced ovarian cancer; gemcitabine for non small cell\\nlung cancer [18] and irinotecan for colorectal cancer\\n[19]. With all these agents, the response rate is low and\\nof short duration, and there are significant side effects.\\nThere has been an increasing trend for manufacturers todisseminate positive information about their anti-cancerdrugs through press releases and by using local public\\nrelations firms. In this way, demands are created which\\ncan disturb the financing of a logical cancer priority\\nladder (Table 4). Education of political decision makers\\nas well as the public is essential to correct this imbalance.\\nThere are many drugs currently in clinical trial. These\\ninclude complex Pharmaceuticals such as cytokines,\\nanti-angiogenesis agents, growth factor inhibitors, mono-\\nclonal antibodies, vaccines and gene therapy\\n [20].  There\\nis no doubt that the recent molecular revolution will\\nresult in novel strategies to selectively destroy cancer\\ncells.  However, aggressive public relations activities by\\nbiotechnology companies, universities and cancer char-ities has led to a significant but as yet unfulfilled public\\nexpectation. Patients and their families need to be made\\naware of the experimental nature of such therapies andthe high chance of failure of early studies. Enhanced\\npublic education is required to explain the complexities\\nof\\n new cancer drug investigation.\\nHigh-dose therapy\\nThere is compelling evidence for a strong relationship\\nbetween dose intensity of chemotherapy and tumour re-sponse rate\\n [21].  The development of recombinant bone\\nmarrow colony stimulating factors has promoted the useof\\n high  dose marrow toxic drug regimens some of which\\ninvolve either autologous bone marrow or peripheralblood stem cell rescue. Despite many publications inthis area firm evidence of effectiveness has only beenreported for certain leukaemias and relapsed lympho-\\nmas. Data from randomised clinical trials are still\\nneeded for other tumours and all such patients shouldbe encouraged to participate in such a study. The highdirect and indirect costs of such therapy together withits huge consumption of expertise, precludes its appro-priateness in low resource environments where essential\\ndrugs are often lacking [22].\\nSupportive care drugs\\nMost effective cancer chemotherapy has significant side\\neffects. Emesis and bone marrow damage predisposing\\nto life threatening sepsis, may be reduced by pharmaco-\\nlogical intervention. Cancer patients frequently developother problems requiring drug therapy not due to med-ication.\\nEffective antiemetics are now available and should be\\nadministered routinely in advance with most chemo-\\ntherapy combinations. We classify the availability ofsteroids, a dopamine receptor antagonist (domperidone,\\nmetoclopramide, prochlorperazine) and a 5-HT\\n3 recep-', mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='9dcb7ae0-c69a-4c43-9e06-4d771d6605be', embedding=None, metadata={'page_label': '389', 'file_name': 'test.pdf', 'file_path': '..\\\\data\\\\test.pdf', 'file_type': 'application/pdf', 'file_size': 527692, 'creation_date': '2024-10-12', 'last_modified_date': '2024-10-12'}, excluded_embed_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], excluded_llm_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], relationships={}, text=\"389\\ntor antagonist (granisetron, ondansetron, tropisetron) as\\nessential. There is no convincing evidence that any\\nparticular agent in either of these groups of drugs is\\npreferred [23]. Local price should thus be the majordeterminant of choice. 5-HT\\n3 antagonists are clearly\\nmore justified in those patients receiving highly emeto-\\ngenic regimens such as those containing cisplatin.\\nNeutropenia and the risk of infection is one of the\\nmost common dose limiting side effects of cancer chemo-\\ntherapy, leading to reduced dosages, delayed cycles and\\nreduced effectiveness. Recombinant colony stimulating\\nfactors (CSF) are available, which mobilise marrow stem\\ncells - filgrastim, lenograstim and molgrastim. There is\\nno good evidence that their routine use enhances the\\noverall effectiveness or safety of standard dose chemo-therapy [24] and so these agents are not classified as\\nessential. These drugs are also used to generate stemcells to salvage patients after high-dose chemotherapy.Anaemia can be treated with blood transfusion. The useof recombinant erythropoietin is therefore not essential.\\nA wide range of relatively cheap drugs are available\\nfor the relief of a range of symptoms experienced by\\ncancer patients\\n [25].  Especially important are the opioid\\nanalgesics which are often strictly controlled and essen-\\ntially unavailable in effective quantities in many coun-\\ntries.  Education of politicians, legislators and health\\ncare professionals is necessary to reduce the immense\\namount of unecessary suffering caused by inadequateanalgesic use [26].\\nChemotherapy delivery\\nThe organization of chemotherapy delivery services has\\ndramatically altered over the last ten years. Most drugs,\\neven in complex regimens, are now given in the out-\\npatient setting rather than in a hospital ward. This has\\nresulted in the concept of nurse led chemotherapy day\\ncare suites, where specially trained nurses supervise the\\nadministration of chemotherapy and in some countries\\ncan now prescribe supportive care drugs [27]. Central-\\nising chemotherapy services creates considerable savingsby reducing wastage and allowing the development of\\ncoordinated drug policies [28]. Day care is preferred by\\npatients and their carers. The WHO strongly supports\\nthe development of nurse led day chemotherapy suites in\\nall hospitals dealing with cancer patients.\\nConclusion\\nThe epidemiology of cancer in various settings and\\ndiffering local health priorities means that individual\\nrequirements for cancer drugs will vary. Nevertheless\\nthe essential drug concept can be applied using the prior-ity banding described. It is vital to continually assess the\\noverall effectiveness of available drugs in the light of\\n new\\nclinical trial data. A curable cancer programme is a\\nuseful tool for political persuasion by taking positive\\naction against the disease. It forms a major part of theWHO cancer priority ladder for effective cancer control\\n(Table 4). Research is urgently needed in simplifying\\nregimens for use in geographically disperse poor areas.\\nThe establishment of rigorous audit and assessment\\nstrategies will enhance the cost effectiveness of chemo-\\ntherapy. The introduction of an analytic culture evenin low resource settings provides the basis for future\\nclinical research programmes [29]. The pharmaceutical\\nindustry have found it difficult to implement a pricebanding system in which poorer countries obtain drugs\\nat lower prices. Parallel importing by wholesalers simply\\nshifts the drugs obtained more cheaply back to the richer\\ncountries with profits taken by those involved at each\\nstep of the process. Establishing an essential drug list\\nand monitoring the availability of its components willhelp to improve the global quality of cancer care.\\nReferences\\n1 World Health Organization. National Cancer Control Pro-\\ngrammes. Policies and Managerial Guidelines. Geneva: WHO\\n1995.\\n2. Sikora K. Developing a global strategy for cancer. Eur J Cancer\\n1999 (in press).\\n3. Stiller C. Centralised treatment, entry to trials and survival. Br J\\nCancer 1994; 70: 352-62.\\n4. World Health Organization. Essential Drugs for Cancer Chemo-\\ntherapy: Memorandum From a WHO Meeting. Bulletin of the\\nWHO 1985; 63-999-1002\\n5. WHO Consultation. Essential Drugs for Cancer Chemotherapy.\\nBulletin of the World Health Organization 1994; 72: 693-8.\\n6. Sobin LH, Fleming ID (eds). TNM Classification of Malignant\\nTumours, 5th edition. Geneva: UICC 1997.\\n7. Benjamin I, Glodwein JW, Rubin SC et al. Oncolink: A cancer\\ninformation resources for oncologists and the public on theinternet. Gynecol Oncol 1996; 60: 8-15.\\n8. Karjalainen S, Palva I. Do treatment protocols improve end\\nresults. BMJ 1989; 299: 1069-72.\\n9. Early Breast Trialist's Collaborative Group Systematic treatment\\nof early breast cancer by hormonal, cytotoxic or immune therapy.\\nLancet 1992; 339: 1-15.\\n10. Fuchs CS, Mayer RJ. Adjuvant chemotherapy for colon and\\nrectal cancer. Semin Oncol 1995; 22: 472-87.\\n11. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide\\nand cisplatin compared with paclitaxel and cisplatin in patientswith stage III and IV ovarian cancer. N Engl J Med 1996; 334:\\n1-6.\\n12. Piccart MJ, Bertelsen K, Stuart G et al. Is cisplatin-paclitaxel\\nstandard in first-line treatment of advancerd ovarian cancer? ProcAm Soc Clin Oncol 1997: 16: 3 (Abstr 1258).\\n13. McGuire W, Neugut A, Arikaian S et al. Analysis of the cost\\neffectiveness of paclitaxel as an alternative combination therapy\\nfor advanced ovarian cancer. J Clin Oncol 1997; 15: 640-5.\\n14. Debruyne FM, Dijkman GA. Advances and trends in hormonal\\ntherapy for advanced prostate cancer. Eur Urol 1995: 28: 177-88.\\n15. Anonymous. Paclitaxel and docetaxel in breast and ovarian\\ncancer. DrugTher Bull 1997; 35: 43-6.\\n16. Rustin GJ, Nelstrop AE, Crawford M. Phase II trial of oral\\naltretamine for relapsed ovarian carcinoma. J Clin Oncol 1997;\\n15: 172-6.\\n17. Creemers GJ, Bolis G, Gore M et  al. Topotecan, an active drug in\\nthe second-line treatment of epithelial ovarian cancer. J Clin\\nOncol 1996; 14:3056-61.\\n18. Bunn PA. The emerging role of gemcitabine in lung cancer. Semin\\nOncol 1997; 24: S7-1.\", mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='397b3d6d-0bea-42b9-8324-b44ff5aee5e9', embedding=None, metadata={'page_label': '390', 'file_name': 'test.pdf', 'file_path': '..\\\\data\\\\test.pdf', 'file_type': 'application/pdf', 'file_size': 527692, 'creation_date': '2024-10-12', 'last_modified_date': '2024-10-12'}, excluded_embed_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], excluded_llm_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], relationships={}, text='390\\n19. Bertino JR. Irinotecan for colorectal cancer. Semin Oncol 1997;\\n24: S18-3.\\n20. Sikora K. Gene therapy in developing countries. Gene Ther 1998;\\n5:3-4.\\n21. Frei E, Cannellos GP. Dose, a critical factor in cancer chemo-\\ntherapy. Am J Med 1986; 69: 585-9.\\n22. Waters TM. Economic analysis of new technologies: the case for\\nstem cell therapy. J Clin Oncol 1997; 15: 2-4\\n23. Roila F, Ballaton E, Tonato M et al. 5-HT 3 receptor antagonists:\\nDifferences and similarities. Eur J Cancer 1997; 33: 1364-70.\\n24. Baldini E, Tibaldi C, Lencioni M et al. Filgrastim and lack of\\nsupport of intensive adjuvant chemotherapy for high risk breast\\ncancer patients. Am J Clin Oncol 1997; 20: 169-72.\\n25. World Health Organization. Symptom Relief in Terminal Illness.\\nGeneva: WHO 1998.\\n26. World Helath Organization. Cancer Pain  Relief.  With a Guide to\\nOpioid Availability. Geneva: WHO 1998.27. Courtenay M, Butler M. Nurse prescribing - the knowledge base.\\nNurs Times 1998; 94: 40-2.\\n28. Esparza DM, Young N, Luongo JA. Effective planning for office\\nand outpatient chemotherapy administration. Semin Oncol Nurs\\n1989;  5: 8-14.\\n29. Monographs. Integrating Economic Analysis into Cancer Clin-\\nical Trials - American Society of Clinical Oncology Economics\\nWorkbook. J Natl Cancer Inst 1998; 24.\\nReceived 13 October 1998; accepted 22 December 1998.\\nCorrespondence to:\\nK. Sikora\\nWHO Programme on Cancer Control\\nInternational Agency for Research on Cancer\\n150 cours Albert Thomas\\n69372 Lyon Cedex 08\\nFrance', mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n')]"
      ]
     },
     "execution_count": 11,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "documents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {},
   "outputs": [],
   "source": [
    "def chunk_document(documents):\n",
    "\n",
    "    base_splitter = SentenceSplitter(chunk_size=512)\n",
    "    splitter = SemanticSplitterNodeParser(\n",
    "        buffer_size=1, breakpoint_percentile_threshold=95, embed_model=embed_model, base_splitter=base_splitter\n",
    "    )\n",
    "    chunks = splitter.get_nodes_from_documents(documents)\n",
    "\n",
    "    return chunks\n",
    "\n",
    "# Chunk your documents before passing them to the index + Flatten the list of chunks\n",
    "# chunked_data = [chunk for documents in documents for chunk in chunk_document(documents)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "chunks = chunk_document(documents)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "'Annals of Oncology 10: 385-390, 1999.\\n© 1999 Kluwer Academic Publishers. '"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "chunks[0].text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "Document()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(id_='1f92cdfe-7418-4416-8c0a-a6bc0b5f4ec7', embedding=None, metadata={}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Annals of Oncology 10: 385-390, 1999.\\n© 1999 Kluwer Academic Publishers. ', mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='b9dc169d-fc64-4ff2-8d7d-70875a6df27e', embedding=None, metadata={}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text=\"Printed  in the Netherlands.\\nSpecial article\\nEssential drugs for cancer therapy:  A World Health Organization\\nconsultation\\nK. Sikora,1 S. Advani,2 V. Koroltchouk,1 I. Magrath,3 L. Levy,4 H. Pinedo,5 G. Schwartsmann,6\\nM.Tattersall7 & S.Yan8\\n1 WHO Cancer Programme, International Agency for Research on Cancer, Lyon, France; 2Department of Medical Oncology, Tata Memorial\\nHospital, India; 3National Cancer Institute, Bethesda, MD, USA, 4 Department of Medicine, University of Zimbabwe, Harare, Zimbabwe,\\niVrije Universiteit, Department of Medical Oncology. Amsterdam, The Netherlands; 6 Hospital de Clinicas de Porto Alegre, Universidade Federal\\ndo Rio Grande do Sul, Porto Alegre, Brazil; ''Department of Cancer Medicine, University of Sydney, Australia; 8 Department of Medical Oncology,\\nCancer Hospital, Chinese Academy of Medical Sciences, Beijing, China\\nSummary\\nThe WHO has previously produced recommendations on the\\nessential drugs required for cancer therapy. Over the last five\\nyears several new anti cancer drugs have been aggressivelymarketed. \", mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='e2f4c686-927b-4de4-801b-e01739b0b85e', embedding=None, metadata={}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Most of these are costly and produce only limitedbenefits.\\n We have divided currently available anti-cancer drugs\\ninto three priority groups. Curable cancers and those cancerswhere the cost-benefit ratio clearly favours drug treatment canbe managed appropriately with regimens based on only\\n 17 drugs.\\nAll of these are available, at relatively low cost, as genericpreparations. The wide availability of these drugs should be\\nthe first priority. The second group of drugs may have some\\nadvantages in certain clinical situations. Based on currentevidence, drugs in the third group are judged as currently notessential for the effective delivery of cancer care. Adequate\\nsupportive care programmes with the widespread availabilityof effective drugs for pain control are of considerably greaterimportance. The adoption of these priorities will help tooptimise the effectiveness and efficiency of chemotherapy and\\nensure equitable access to essential drugs especially in low\\nresource environments. Clearly this paper represents the views\\nof its contributors. The WHO welcomes feedback from alloncologists so that the advice it gives to governments in priori-tising the procurement of anti cancer drugs can be as compre-hensive as possible.\\nKey words: chemotherapy, drugs, generics, prioritization\\nIntroduction\\nCancer is an important and increasing cause of morbidity\\nand mortality worldwide. Currently, 10 million new\\ncancer patients are detected each year and six million\\npeople die of the disease. We estimate that these figureswill be 20 million and\\n 10 million respectively by the year\\n2020.  Many cancer patients, if diagnosed at an early\\nstage and given appropriate treatment, will subsequentlylive a normal life-span. Useful palliation can be achieved\\nfor all patients. Effective cancer care requires the linkage\\nof early diagnosis to the appropriate use of surgery,radiotherapy, cytotoxic and endocrine therapies as well\\nas supportive care including analgesics, antibiotics, and\\nblood products. Such treatments may be complex in-volving different specialists and not all may be availablein every hospital. They are also costly making theoptimal organisation of cancer services important in all\\neconomic environments.\\nThe provision of cancer treatment services, including\\nchemotherapy, is an essential component of a nationalcancer programme (NCP). These programmes offer a\\nrational mechanism for implementing existing knowl-\\nedge on primary prevention, early diagnosis, screening,optimal treatment services and symptom control. The\\nWHO has produced a cancer priority ladder which can beadapted to the resources available and the epidemiology\\nof cancer in a specific country. The formation of\\n an NCP\\nis an important health priority [1,  2]. Even with limited\\nresources, a systematic, planned approach can yield sub-\\nstantial medical and social benefits. Some common\\ntumours can be treated with a good chance of cure, so\\nthat treatment services should be readily accessible.Some relatively rare but curable cancers require highly\\nspecialised facilities for optimal care such as the acute\\nleukaemias and paediatric tumours\\n [3]. Unless adequate\\nresources and facilities are available, it is inappropriate\\nto acquire the drugs which are required to treat these\\ncancers. For other tumours such as hepatoma and lungcancer the development of effective prevention pro-grammes through hepatitis\\n B immunisation and tobacco\\ncontrol will clearly be of greater priority than therapyfor the immediate future. Downstaging strategies inbreast and cervical cancer by early detection programmes\\nand effective referral guidelines will provide a larger\\nhealth gain in certain situations. The cost effectivenessof chemotherapy will clearly vary across the globally\\ndiverse epidemiological and economic spectrum.', mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='15a06270-0e4b-42b2-9be1-6f02819c0a3f', embedding=None, metadata={}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='386\\nCancer chemotherapy, like surgery and radiation ther-\\napy is an essential component of modern cancer care.\\nMedical staff must have appropriate training, knowl-\\nedge and access to the requisite facilities to deliver and\\nmonitor chemotherapy. A properly directed and inte-grated team approach with experts in at least pathology,\\nsurgery, radiation therapy and medicine is essential foroptimal outcomes at an acceptable cost.\\nTo assist the WHO Expert Committee on the Use of\\nEssential Drugs in their selection of drugs for cancer\\nchemotherapy, the WHO invited medical oncologists\\nfrom five continents to review the essential drugs list for\\ncancer which had been formulated initially in 1985 [4]\\nand revised in 1994 [5].\\nGeneral principles\\nPrior to the initiation of any cancer treatment, the goal\\nof therapy must be realistically defined. ', mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='962312f1-9b89-43c8-a7df-793f7b5ba056', embedding=None, metadata={}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text=\"Individual prog-\\nnostic factors should be determined such as the stage of\\ndisease [6], the sites of metastases, the histology of the\\ntumour, the general medical status of the patient, the\\npatient's willingness to accept the anticipated toxicity,\\nand the availability of necessary facilities and personnel\\nto treat complications. Although a particular tumour\\ntype may be curable in some instances, clearly not allpatients with that tumour type will be cured. The risk -benefit concept needs to be discussed with the patient inadvance. Increasingly patients are being given far moreinformation about cancer and the options available tothem. Furthermore the Internet provides a readily ac-\\ncessible international resource on cancer including\\ndrugs and is used by many patients and their families\\n[7]. Commonly used sites include Oncoweb, Oncolink,\\nCancernet, PDQ. These are well contructed sites with\\nreliable information. Unfortunately, the quality of many\\nother sites is highly variable. Cancer chemotherapy\\nrequires access to laboratory facilities to monitor blood\\ncounts as well as liver and renal function. The assessment\\nof tumour response in patients with measurable tumours\\nmust be made at appropriate intervals to determine if\\nthe treatment is effective and if the patient should con-tinue therapy.\\nSome principles of chemotherapy are well established.\\nThe initial therapies employed are often the most impor-\\ntant in determining their outcome\\n [8]. Therapy should not\\nbe unnecessarily delayed, nor should a suboptimal treat-ment programme be given. Managers and patients must\\nunderstand that simply reducing the standard dosage\\nadministered or the number of courses given to save\\ncosts is unacceptable. For tumours sensitive to chemo-\\ntherapy a combination of drugs, each employed at an\\noptimal dose, is more likely to induce tumour responseand result in meaningful benefit. The treatment of pa-\\ntients with a minimal tumour burden is usually more\\neffective. The results of numerous clinical trials in recent\\nyears clearly demonstrate that certain patient groupswith operable breast [9] and colorectal cancer [10] sur-vive longer when given systemic therapy after tumour\\nresection. The implications of these new data are that a\\nlarge number of additional patients may benefit from\\nchemotherapy. Recently several high cost drugs have\\nbeen marketed for common cancers. Although capable\\nof a significant response rate in patients with metastatic\\ndisease, such responses are often of short duration and\\nmay only prolong median survival by a few weeks to\\nmonths. To what extent some of these new drugs should\\nreplace older and cheaper agents has not yet been deter-\\nmined in well designed trials with relevant endpoints\\nincluding cost benefit assessment. Prioritisation mustbe based on the relative efficacy and cost effectiveness of\\nspecific drugs\\n [11].  Inevitably this will have a subjective\\nelement and will vary with the overall allocation tocancer treatment in a country.\\nTumour categories\\nThere are more than 200 types of cancer and these\\nrespond variably to chemotherapy. Tumours can be use-\\nfully split into five categories with regard to the relativeusefulness of chemotherapy. This provides a basis for\\nexamining the overall health gain of defined interven-\\ntions.\\nCategory  1. Tumours for which there is evidence that\\nthe use of a single or a combination of drugs used aloneor with other therapeutic modalities will result in cure as\\ndefined by a normal life-span in some and a prolonga-\\ntion of survival in most patients.\\nCategory 2. Tumours where the average survival is\\nprolonged when chemotherapy is used as an adjuvantto local surgery or radiotherapy in early stages of dis-\\nease.\\nCategory  3. Tumours for which there is evidence that\\nthe use of  one drug or a combination of drugs will cause\\ntumour shrinkage in more than 20% of selected patientswith metastatic disease with almost certain improve-ment in the quality of life. Prolongation of survivaloccurs in most of the responding patients but may be of\\nshort duration.\\n\", mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='0442b71b-52f4-4052-968b-38e0d5490dd9', embedding=None, metadata={}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Category 4. Tumours where local control may be im-\\nproved by the use of chemotherapy before, during orafter surgery and radiotherapy.\\nCategory  5. ', mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='de279103-29a4-4eac-adb5-a217f4a09987', embedding=None, metadata={}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Tumours for which there are currently no\\neffective drugs. Objective responses occur in less than\\n20% of patients and there is no evidence of survival\\nbenefit in randomised controlled trials when comparedto best supportive care.\\nTable 1 divides the commonly occurring cancers into\\neach of these\\n five categories.', mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='7bc215ec-d88e-4474-a300-0519d51c5ce0', embedding=None, metadata={}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text=\"387\\nTable 1. Cancers grouped according to the effectiveness of chemo-\\ntherapy and hormonal therapy.\\nCategory 1. potentially curable even with systemic disease\\nGerm-cell cancers\\nTrophoblastic cancers\\nAcute lymphoblastic leukaemiaAcute myeloid leukaemiaAcute promyelocytic leukaemia\\nHairy cell leukaemia\\nHodgkin's disease and non-Hodgkin's lymphoma\\nCategory 2. adjuvant chemotherapy of established benefit in local\\ndisease\\nColo-rectal cancer (Dukes C)\\nBreast cancer\\nOvarian cancer\\nOsteosarcoma\\nEwing's sarcomaNeuroblastoma\\nRetinoblastoma\\nSoft tissue sarcoma\\nWilms' tumour\\nCategory 3, palliative benefit only in metastatic disease\\nLung cancer\\nSmall-cell - relatively long durationNon-small-cell - relatively short duration\\nOvarian cancer\\nChronic lymphocytic and myelogeneous leukaemia\\nAnal cancer\\nBladder cancerEndometrial cancerProstate cancer\\nKaposi's sarcoma (non-HlV)\\nIndolent AIDS-related lymphoma and Kaposi's sarcoma\\nAdult soft tissue sarcoma\\nColorectal cancer\\nCervical cancer\\nHead and neck cancer\\nOesophageal cancer\\nStomach cancer\\nBreast Cancer\\nCategory 4, local control enhanced\\nOropharyngeal cancer\\nNasopharyngeal cancer\\nCategory 5, chemotherapy ineffective\\nAIDS-related CNS lymphoma\\nHepatobiliary cancersMelanomaPancreatic cancerRenal-cell cancer\\nThyroid cancer\\nCentral nervous system cancers\\nPrioritising anti-cancer drugs\\nWe have banded anti-cancer drugs into three priority\\nlevels.  The determination of the priority grouping of a\\ndrug is based on its utility in treating category 1, 2 and 3\\ntumours and the global incidence of the responding\\ntumours. Table 2 shows the effects of systemic therapy\\nin the treatment of  the ten most common cancers world-\\nwide. Unfortunately, good responses outside the adjuvant\\nsituation are limited for most of these tumours. We haveidentified 13 effective drugs which provide beneficialTable 2. Effects of systemic therapy on the ten most common cancers\\nworldwide.\\nCancer Category\\nLung\\nStomach\\nBreast\\nColorectal\\nCervix\\nHead and neck\\nLymphomaHepatobiliary\\nOesophagus\\nProstate\\nTable  3. \", mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='c2b7aadc-3062-45e5-ba07-9d2867c96509', embedding=None, metadata={}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Cancer drug priority list.\\nTop 10 cancers Category 1-2 Generic\\nPriority 1\\nBleomycin + + +\\nChlorambucil + + +\\nCisplatin + + +\\nCyclophosphamide + + +\\nDoxorubicin + + +\\nEtoposide + + +\\n5-Fluorouracil  + + +\\nMethotrexate + + +Prednisolone + + +\\nProcarbazine + +\\nTamoxifen + + +\\nVincristine + + +Vinblastine + + +Cytarabine + +\\nDactinomycin + +\\nDaunorubicin + +\\n6-Mercaptopurine  + +\\nTogether with two antiemetics - a dopamine receptor and a  5-HT 3\\nreceptor antagonist as well as dexamethasone\\nPriority 2\\nBusulphan + +\\nCarboplatin +\\nFlutamide +\\nFolinic acid + +\\nInterferon alpha +LHRH analogues +\\nMelphalan +\\nMegestrol acetate + +Mitomycin C +Mitoxantrone + +\\nPaclitaxel +\\nVinorelbine +\\nPriority 3\\nAminoglutethimide + +Anastrozole +\\nAltretamine\\nBCNU, CCNU +\\nDacarbazine +Docetaxel +\\nEpirubicin + +\\nGemcitabine +\\nIfosfamide\\nIrinotecan +\\nRaltitrexed +\\nTopotecan', mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='bad4b386-dc15-400b-8aff-c659325cb33e', embedding=None, metadata={}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='388\\nTable  4. The WHO cancer priority ladder.\\nTobacco control.\\nInfection control.\\nCurable cancer programme.\\nEffective pain control.\\nEarly detection strategy.\\nSample cancer registry.\\nHealthy eating programme.\\nReferral guidelines.\\n', mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='3afb3960-bab9-48f4-a631-72c9d5cd353c', embedding=None, metadata={}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Clinical care guidelines.\\nNurse education.\\nNational cancer network.\\nClinical evaluation unit.\\nPlatform technology focus for region.\\nClinical research programme.\\nBasic research programme.\\nInternational aid programme.\\noutcomes against certain common tumours (Table 3)\\nwith a further four drugs necessary for the treatment ofleukaemia. Thus, 17 drugs can be considered in priority\\none and are thus essential. In preparing this list of drugs,\\nevidence of benefit was accepted only from scientifically\\nvalid clinical research. This has permitted the rationalselection of essential drugs from more than 100 commer-\\ncially available preparations. All 17 are widely available\\nas generic preparations of relatively low cost.\\nA second group of drugs is listed in priority 2. These\\nhave well documented benefits in certain clinical situa-\\ntions.  They are not truly essential as either drugs from\\nthe priority 1 list can be used as substitutes or their\\neffects are only palliative. Cheaper and simpler forms of\\npalliation with radiotherapy or analgesics may be more\\nappropriate in low resource environments. Few of these\\ndrugs are available as generic preparations. The taxanes\\nhave generated considerable public interest. A rando-mised controlled trial in the USA demonstrated a 13month survival advantage for women treated with pacli-taxel and cisplatin as first line chemotherapy for ovarian\\ncancer when compared to cyclophosphamide and cis-\\nplatin [11]. This has been confirmed by a Canadian-\\nEuropean study\\n [12].  ', mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='c77558e8-ac5b-4f85-8281-ea05b2d291fb', embedding=None, metadata={}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Several studies are still in progress\\nto verify these results. The additional cost of the taxane\\nper quality adjusted life year (QUALY) has been calcu-lated at USS2000 per patient [13]. Paclitaxel wouldtherefore move into priority 1 group if its benefit is\\nclearly reproducible. The use of paclitaxel as second or\\nthird line therapy is not cost effective with a cost perQUALY of over US$30,000. The LHRH analogues are\\nuseful in palliating metastatic prostate cancer [14].\\nAlthough effective, they are costly and require frequent\\nclinic attendances. ', mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='cb6b9270-6178-4a5d-873c-b9122a32a902', embedding=None, metadata={}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Prostate cancer is dramatically in-creasing in incidence globally due to ageing populations.\\nAn oral formulation could change the priority category.\\nMany of the drugs in the priority three group are\\nrecent, expensive and of\\n low effectiveness. About half  of\\npatients with metastatic breast cancer respond to doce-taxel. The side effects are significant and the median\\nresponse duration is only five to six months [15]. Altret-amine [16] and topotecan [17] are being marketed for\\nadvanced ovarian cancer; gemcitabine for non small cell\\nlung cancer [18] and irinotecan for colorectal cancer\\n[19]. With all these agents, the response rate is low and\\nof short duration, and there are significant side effects.\\n', mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='190237c4-2a60-4bd6-a4d1-c059c3efa20e', embedding=None, metadata={}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='There has been an increasing trend for manufacturers todisseminate positive information about their anti-cancerdrugs through press releases and by using local public\\nrelations firms. In this way, demands are created which\\ncan disturb the financing of a logical cancer priority\\nladder (Table 4). Education of political decision makers\\nas well as the public is essential to correct this imbalance.\\nThere are many drugs currently in clinical trial. These\\ninclude complex Pharmaceuticals such as cytokines,\\nanti-angiogenesis agents, growth factor inhibitors, mono-\\nclonal antibodies, vaccines and gene therapy\\n [20].  There\\nis no doubt that the recent molecular revolution will\\nresult in novel strategies to selectively destroy cancer\\ncells.  However, aggressive public relations activities by\\nbiotechnology companies, universities and cancer char-ities has led to a significant but as yet unfulfilled public\\nexpectation. Patients and their families need to be made\\naware of the experimental nature of such therapies andthe high chance of failure of early studies. Enhanced\\npublic education is required to explain the complexities\\nof\\n new cancer drug investigation.\\nHigh-dose therapy\\nThere is compelling evidence for a strong relationship\\nbetween dose intensity of chemotherapy and tumour re-sponse rate\\n [21].  The development of recombinant bone\\nmarrow colony stimulating factors has promoted the useof\\n high  dose marrow toxic drug regimens some of which\\ninvolve either autologous bone marrow or peripheralblood stem cell rescue. Despite many publications inthis area firm evidence of effectiveness has only beenreported for certain leukaemias and relapsed lympho-\\nmas. Data from randomised clinical trials are still\\nneeded for other tumours and all such patients shouldbe encouraged to participate in such a study. The highdirect and indirect costs of such therapy together withits huge consumption of expertise, precludes its appro-priateness in low resource environments where essential\\ndrugs are often lacking [22].\\nSupportive care drugs\\nMost effective cancer chemotherapy has significant side\\neffects. Emesis and bone marrow damage predisposing\\nto life threatening sepsis, may be reduced by pharmaco-\\nlogical intervention. Cancer patients frequently developother problems requiring drug therapy not due to med-ication.\\nEffective antiemetics are now available and should be\\nadministered routinely in advance with most chemo-\\ntherapy combinations. We classify the availability ofsteroids, a dopamine receptor antagonist (domperidone,\\nmetoclopramide, prochlorperazine) and a 5-HT\\n3 recep-', mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='12674ec4-346f-40b8-bbd8-801e67bd8e9c', embedding=None, metadata={}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text=\"389\\ntor antagonist (granisetron, ondansetron, tropisetron) as\\nessential. There is no convincing evidence that any\\nparticular agent in either of these groups of drugs is\\npreferred [23]. Local price should thus be the majordeterminant of choice. 5-HT\\n3 antagonists are clearly\\nmore justified in those patients receiving highly emeto-\\ngenic regimens such as those containing cisplatin.\\nNeutropenia and the risk of infection is one of the\\nmost common dose limiting side effects of cancer chemo-\\ntherapy, leading to reduced dosages, delayed cycles and\\nreduced effectiveness. Recombinant colony stimulating\\nfactors (CSF) are available, which mobilise marrow stem\\ncells - filgrastim, lenograstim and molgrastim. There is\\nno good evidence that their routine use enhances the\\noverall effectiveness or safety of standard dose chemo-therapy [24] and so these agents are not classified as\\nessential. These drugs are also used to generate stemcells to salvage patients after high-dose chemotherapy.Anaemia can be treated with blood transfusion. The useof recombinant erythropoietin is therefore not essential.\\nA wide range of relatively cheap drugs are available\\nfor the relief of a range of symptoms experienced by\\ncancer patients\\n [25].  Especially important are the opioid\\nanalgesics which are often strictly controlled and essen-\\ntially unavailable in effective quantities in many coun-\\ntries.  Education of politicians, legislators and health\\ncare professionals is necessary to reduce the immense\\namount of unecessary suffering caused by inadequateanalgesic use [26].\\nChemotherapy delivery\\nThe organization of chemotherapy delivery services has\\ndramatically altered over the last ten years. Most drugs,\\neven in complex regimens, are now given in the out-\\npatient setting rather than in a hospital ward. This has\\nresulted in the concept of nurse led chemotherapy day\\ncare suites, where specially trained nurses supervise the\\nadministration of chemotherapy and in some countries\\ncan now prescribe supportive care drugs [27]. Central-\\nising chemotherapy services creates considerable savingsby reducing wastage and allowing the development of\\ncoordinated drug policies [28]. Day care is preferred by\\npatients and their carers. The WHO strongly supports\\nthe development of nurse led day chemotherapy suites in\\nall hospitals dealing with cancer patients.\\nConclusion\\nThe epidemiology of cancer in various settings and\\ndiffering local health priorities means that individual\\nrequirements for cancer drugs will vary. Nevertheless\\nthe essential drug concept can be applied using the prior-ity banding described. It is vital to continually assess the\\noverall effectiveness of available drugs in the light of\\n new\\nclinical trial data. A curable cancer programme is a\\nuseful tool for political persuasion by taking positive\\naction against the disease. It forms a major part of theWHO cancer priority ladder for effective cancer control\\n(Table 4). Research is urgently needed in simplifying\\nregimens for use in geographically disperse poor areas.\\nThe establishment of rigorous audit and assessment\\nstrategies will enhance the cost effectiveness of chemo-\\ntherapy. The introduction of an analytic culture evenin low resource settings provides the basis for future\\nclinical research programmes [29]. The pharmaceutical\\nindustry have found it difficult to implement a pricebanding system in which poorer countries obtain drugs\\nat lower prices. Parallel importing by wholesalers simply\\nshifts the drugs obtained more cheaply back to the richer\\ncountries with profits taken by those involved at each\\nstep of the process. Establishing an essential drug list\\nand monitoring the availability of its components willhelp to improve the global quality of cancer care.\\nReferences\\n1 World Health Organization. National Cancer Control Pro-\\ngrammes. Policies and Managerial Guidelines. Geneva: WHO\\n1995.\\n2. Sikora K. Developing a global strategy for cancer. Eur J Cancer\\n1999 (in press).\\n3. Stiller C. Centralised treatment, entry to trials and survival. Br J\\nCancer 1994; 70: 352-62.\\n4. World Health Organization. Essential Drugs for Cancer Chemo-\\ntherapy: Memorandum From a WHO Meeting. Bulletin of the\\nWHO 1985; 63-999-1002\\n5. WHO Consultation. Essential Drugs for Cancer Chemotherapy.\\nBulletin of the World Health Organization 1994; 72: 693-8.\\n6. Sobin LH, Fleming ID (eds). TNM Classification of Malignant\\nTumours, 5th edition. Geneva: UICC 1997.\\n7. Benjamin I, Glodwein JW, Rubin SC et al. Oncolink: A cancer\\ninformation resources for oncologists and the public on theinternet. Gynecol Oncol 1996; 60: 8-15.\\n8. Karjalainen S, Palva I. Do treatment protocols improve end\\nresults. BMJ 1989; 299: 1069-72.\\n9. Early Breast Trialist's Collaborative Group Systematic treatment\\nof early breast cancer by hormonal, cytotoxic or immune therapy.\\nLancet 1992; 339: 1-15.\\n\", mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='1cf61191-f7af-4c25-b821-1c0843d4a591', embedding=None, metadata={}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='10. Fuchs CS, Mayer RJ. Adjuvant chemotherapy for colon and\\nrectal cancer. Semin Oncol 1995; 22: 472-87.\\n11. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide\\nand cisplatin compared with paclitaxel and cisplatin in patientswith stage III and IV ovarian cancer. N Engl J Med 1996; 334:\\n1-6.\\n', mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='fe2015f0-0cef-41ac-b297-022eb121d07d', embedding=None, metadata={}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='12. Piccart MJ, Bertelsen K, Stuart G et al. Is cisplatin-paclitaxel\\nstandard in first-line treatment of advancerd ovarian cancer? ProcAm Soc Clin Oncol 1997: 16: 3 (Abstr 1258).\\n13. McGuire W, Neugut A, Arikaian S et al. Analysis of the cost\\neffectiveness of paclitaxel as an alternative combination therapy\\nfor advanced ovarian cancer. J Clin Oncol 1997; 15: 640-5.\\n', mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='d0805838-79e9-4246-ac71-a492c31158a8', embedding=None, metadata={}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='14. Debruyne FM, Dijkman GA. Advances and trends in hormonal\\ntherapy for advanced prostate cancer. Eur Urol 1995: 28: 177-88.\\n15. ', mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='625ea3b8-bf89-4f7f-9205-fd6e74fe5b83', embedding=None, metadata={}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Anonymous. Paclitaxel and docetaxel in breast and ovarian\\ncancer. DrugTher Bull 1997; 35: 43-6.\\n16. Rustin GJ, Nelstrop AE, Crawford M. Phase II trial of oral\\naltretamine for relapsed ovarian carcinoma. J Clin Oncol 1997;\\n15: 172-6.\\n17. Creemers GJ, Bolis G, Gore M et  al. Topotecan, an active drug in\\nthe second-line treatment of epithelial ovarian cancer. J Clin\\nOncol 1996; 14:3056-61.\\n', mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='abff4848-20a2-4fd5-8136-e45581820c02', embedding=None, metadata={}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='18. Bunn PA. The emerging role of gemcitabine in lung cancer. Semin\\nOncol 1997; 24: S7-1.', mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='32235f88-5471-4290-be95-9ac75b23b572', embedding=None, metadata={}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='390\\n19. Bertino JR. Irinotecan for colorectal cancer. Semin Oncol 1997;\\n24: S18-3.\\n20. Sikora K. Gene therapy in developing countries. Gene Ther 1998;\\n5:3-4.\\n21. Frei E, Cannellos GP. Dose, a critical factor in cancer chemo-\\ntherapy. Am J Med 1986; 69: 585-9.\\n', mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='ded95752-01b8-4932-b47e-192e3eba74c3', embedding=None, metadata={}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='22. Waters TM. Economic analysis of new technologies: the case for\\nstem cell therapy. J Clin Oncol 1997; 15: 2-4\\n23. ', mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='ffbbacf2-415b-4223-8745-de86fe03c188', embedding=None, metadata={}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='Roila F, Ballaton E, Tonato M et al. 5-HT 3 receptor antagonists:\\nDifferences and similarities. Eur J Cancer 1997; 33: 1364-70.\\n24. Baldini E, Tibaldi C, Lencioni M et al. Filgrastim and lack of\\nsupport of intensive adjuvant chemotherapy for high risk breast\\ncancer patients. Am J Clin Oncol 1997; 20: 169-72.\\n25. World Health Organization. Symptom Relief in Terminal Illness.\\nGeneva: WHO 1998.\\n26. World Helath Organization. Cancer Pain  Relief.  With a Guide to\\nOpioid Availability. Geneva: WHO 1998.27. Courtenay M, Butler M. Nurse prescribing - the knowledge base.\\nNurs Times 1998; 94: 40-2.\\n', mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n'),\n",
       " Document(id_='d4fe24e8-1509-428f-9654-b95fcfcd8614', embedding=None, metadata={}, excluded_embed_metadata_keys=[], excluded_llm_metadata_keys=[], relationships={}, text='28. Esparza DM, Young N, Luongo JA. Effective planning for office\\nand outpatient chemotherapy administration. Semin Oncol Nurs\\n1989;  5: 8-14.\\n29. Monographs. Integrating Economic Analysis into Cancer Clin-\\nical Trials - American Society of Clinical Oncology Economics\\nWorkbook. J Natl Cancer Inst 1998; 24.\\nReceived 13 October 1998; accepted 22 December 1998.\\nCorrespondence to:\\nK. Sikora\\nWHO Programme on Cancer Control\\nInternational Agency for Research on Cancer\\n150 cours Albert Thomas\\n69372 Lyon Cedex 08\\nFrance', mimetype='text/plain', start_char_idx=None, end_char_idx=None, text_template='{metadata_str}\\n\\n{content}', metadata_template='{key}: {value}', metadata_seperator='\\n')]"
      ]
     },
     "execution_count": 22,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "[Document(text=chunk.text) for chunk in chunks]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "metadata": {},
   "outputs": [],
   "source": [
    "vector_store = MilvusVectorStore(\n",
    "            dim=1024,\n",
    "            collection_name=\"milvus_test\",\n",
    "            uri=\"http://localhost:19530/\",\n",
    "            overwrite=True\n",
    "        )\n",
    "\n",
    "chunks = chunk_document(documents)\n",
    "storage_context = StorageContext.from_defaults(vector_store=vector_store)\n",
    "vector_store_index = VectorStoreIndex(nodes=chunks,vector_store=vector_store, embed_model=embedder, storage_context=storage_context)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 90,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      " Based on the provided context, tumours can be categorized into five groups:\n",
      "\n",
      "1. Tumours for which the use of a single or a combination of drugs used alone or with other therapeutic modalities will result in a cure as defined by a normal life-span in some and a prolongation of survival in most patients.\n",
      "2. Tumours where the average survival is prolonged when chemotherapy is used as an adjuvant to local surgery or radiotherapy in early stages of disease.\n",
      "3. Tumours for which there is evidence that the use of one drug or a combination of drugs will cause tumour shrinkage in more than 20% of selected patients with metastatic disease, with almost certain improvement in quality of life. Prolongation of survival occurs in most of the responding patients but may be of short duration.\n",
      "4. Tumours where local control may be improved by the use of chemotherapy before, during or after surgery and radiotherapy.\n",
      "5. Tumours for which there are currently no effective drugs. Objective responses occur in less than 20% of patients and there is no evidence of survival benefit in randomised controlled trials when compared to best supportive care.\n",
      "\n",
      "The context also mentions that commonly occurring cancers are divided into these five categories.\n"
     ]
    }
   ],
   "source": [
    "query_engine = vector_store_index.as_query_engine(llm=nim_llm)\n",
    "res = query_engine.query(\"What are the different categories of tumour?\")\n",
    "print(res)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
